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ABSTRACT

THE PREVENTION OF OBESITY-ASSOCIATED COLORECTAL CANCER VIA DIETARY
SUPPRESSION OF INFLAMMATION-DRIVEN WNT-SIGNALING
MAY 2019
JINCHAO LI, B.S., SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
M.S., ANHUI MEDICAL UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Zhenhua Liu

Colorectal cancer (CRC) is the third leading cause of cancer deaths in the United States. A
number of population studies have established that modifiable lifestyle factors such as obesity
plays an important role in colorectal carcinogenesis. In the United States, more than one-third of
adults are obese and obesity prevalence rates have no sign of decrease. Therefore, the
development of effective strategy to prevent obesity-induced CRC is a public health priority.
This study aimed to investigate whether genetic or dietary strategies can prevent obesityinduced CRC and determine the potential molecular mechanisms underlying the prevention
effects of these strategies. We use Apc1638N mice, germline heterozygous mutation in the Apc
gene, and Caco-2 cell line to study intestinal tumorigenesis. Hematoxylin and eosin stain and
QuickPlex SQ 120, a chemiluminescence assay, were used to measure the inflammatory
status. Real time PCR, Western blot assay, and immunohistochemical analysis were used to
further examine the signaling pathway status. We found that loss of Tumor necrosis factor alpha
(TNF-α) decreased obesity associated intestinal tumorigenesis by decreasing the inflammation,
and manipulating the β-catenin pathway and NF-kB signaling. In addition, IKK, component of
the NF-kB signaling, was involved in the regulation of β-catenin pathway. The administration of
Vitamin D (VD), at 5000 IU level, exerted an anti-inflammatory property, and leaded to
vi

suppressed intestinal Wnt-signaling and tumorigenesis in obese mice. The molecular function of
sulforaphane (SFN) on a high dose of VD supplementation, although displayed on the inhibition
of HDAC and the activation of autophagy, needs further investigation. Butyrate can increase the
activity of Wnt/β-catenin pathway. Knocking down FFAR2 by siRNA decreased the expression
of cleaved caspase 3 and the expression of phospho-GSK3β (Ser9) and active β-catenin in
Caco-2 cells, subsequently mitigated the anticancer effect of butyrate.
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CHAPTER 1
INTRODUCTION

Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is
the third most common cancer in the United States, with around 140,000 new cases being
diagnosed last year. The pathogenetic mechanisms underlying CRC development are complex
and include hereditary and environmental factors. There is strong evidence that modifiable
lifestyle factors, including obesity, play a crucial role in CRC carcinogenesis (Gunter and
Leitzmann 2006).

Obesity is epidemic in most western countries and is a major preventable risk factor for CRC
cancer incidence and mortality. Currently, the mechanisms underlying obesity associated CRC
cancer include: chronic low-grade inflammation, altered microbiomes, and increased levels of
hormones, chemokines, and adipocytokines (Berger 2014). Many studies have suggested that
obesity associated chronic inflammation might mediate its complications, such as CRC. It is
suggested that chronic inflammation plays a crucial role in CRC development and progression,
given the fact that multiple inflammatory cells and inflammatory cytokines present in tumor
microenvironments. However, the molecular mechanisms linking obesity associated
inflammation to CRC cancer remain unclear.

There has been considerable interest in the use of diet for cancer prevention. A large amount of
evidence has shown that diet has the potential to influence inflammation status and cancer
1

development. Epidemiological studies have suggested that consumption of vegetables, fruits,
and whole grain is associated with a low inflammation status and reduced risk of CRC cancers.
On the other hand, consumption of red and processed meat is associated with a high
inflammation status and increased risk of CRC cancers. It is generally recognized that
vegetables and fruits such as cruciferous vegetables (broccoli, brussels sprouts, and cabbage),
fiber, whole grain, and some of the vitamins such as Vitamin D might have CRC cancer
prevention effects. However, whether knockout TNF-a, supplementation butyrate, or
combination of Vitamin D with SFN can prevent obesity associated CRC and the precise
molecular mechanisms underlying its CRC cancer prevention effects remain unclear.

Activation of Wnt signaling at the bottom of the intestinal crypts is essential for intestinal
homeostasis (Flanagan, Austin et al. 2018). Hyperactivation of Wnt pathway is present in almost
all CRC. Loss of APC function is crucial in aberrant Wnt signaling in CRC, as previous studies
have shown that different mutations of APC could result in different levels of activity of canonical
Wnt pathway and subsequent CRC incidence (Christie, Jorissen et al. 2013). In addition,
inflammatory cytokines such as TNF-a might activate Wnt pathway (Liu, Brooks et al. 2012;
Bradford, Ryu et al. 2017).

My dissertation aims to investigate whether knockout TNF-a, combination of Vitamin D with
SFN, or supplementation of butyrate, can prevent obesity associated CRC and whether
inhibition of inflammation and subsequent inhibition of Wnt pathway are involved in the cancer
prevention effects of those strategy.

2

CHAPTER 2
LITERATURE REVIEW

2.1 Colorectal cancer
2.1.1 Epidemiology of CRC
Colorectal cancer (CRC) is the third leading cause of cancer death in the United States in both
men and women. In 2018, it is estimated that ≈ 64 640 women and 75 610 men in the United
States were diagnosed with CRC and 23 240 women and 27 390 men died from CRC. The
pathogenesis of CRC development is complex. Both genetic and environmental factors may
play an important role in the development of CRC (De Rosa, Pace et al. 2015). Almost 75% of
CRC do not have positive family history and are sporadic. Only 25% of CRC cases have
positive family history.

2.1.2 Environmental factors
The environmental risk factors of CRC development include obesity, smoking, heavy drinking,
high intake of red meat and processed meat. It is estimated that every unit increase of the BMI
is associated with 2-3% increased risk of developing CRC. Heavy drinking and smoking is
associated with 20-50% increased risk of developing CRC (Liang, Chen et al. 2009; Fedirko,
Tramacere et al. 2011). Every 100 g increase of consumption of red meat and processed meat
is associated with 16% increased risk of CRC (Song, Garrett et al. 2015).

3

On the other hand, increased intake of Vitamin D, fiber, vegetables, whole grains are associated
with decreased risk of CRC. In addition, 30 minutes of moderate activity can decrease the risk
of CRCs by 10%(Arem, Moore et al. 2014). Clinic studies also have shown that long term use of
low-dose of aspirin can prevent the incidence of CRC (Algra and Rothwell 2012).

2.1.3 Pathogenesis of CRC
The above risk factors can cause normal colon epithelial cells into benign polyps and
subsequently into malignant carcinomas by activating oncogenes and deactivating tumor
suppressor genes through long term accumulation of genetic mutations and alteration of
epigenetics. As shown in Figure 2.1, the top one shows the well recognized pathway: from
tubular adenomas to adenocarcinomas. The bottom one shows a recently described pathway:
from serrated polyps to serrated colorectal cancer.

Figure 2.1 Pathogenesis of CRC. Source: Ernst J. Kuipers. Colorectal cancer. Nature Reviews
Disease Primers volume 1, Article number: 15065 (2015). Available at
https://www.nature.com/articles/nrdp201565
4

There are three distinct pathogenesis mechanisms by which CRC develop: the chromosomal
instability (CIN), microsatellite instability (MSI), CpG island methylator phenotype (CIMP). CIN is
composed of 85% of CRC. MSI is caused by loss of DNA mismatch repair activity, occurring in
about 15% of all CRC (Bogaert and Prenen 2014). CIMP is characterized by a widespread CpG
island methylation (Nazemalhosseini Mojarad, Kuppen et al. 2013). Loss function of APC plays
a pivotal role in the development of CIN phenotype CRC. In my dissertation, I focused on the
most common CRC: CIN phenotype.

2.1.4 Prevention of CRC
CRC can be prevented by altering the modifiable factors such as unhealthy diet and lifestyle
factors. Since previous studies have shown that high intake of red meat, processed meat, highly
refined grains and starches, and sugars are associated with increased risk of CRC. Therefore,
decreasing the consumption of those foods and intake more fiber, vegetable, fruits, beans, and
unsaturated fatty acids might lower the risk of CRC. There are also many studies indicating that
increased intake of calcium and Vitamin D might lower risk of CRC. Long term and small dose
of Aspirin and Satin usage might prevent the incidence of CRC. However the role of these
interventions in the prevention of CRC remains controversial. In terms of lifestyle, researchers
found that quit smoking and heavy drinking, avoiding of obesity, and regular physical activity
may have the benefit of reducing the risk of CRC (Chan and Giovannucci 2010).

2.2 Obesity and obesity associated inflammation

5

Obesity, an epidemic, can increase many chronic diseases, such as diabetes, chronic heart
diseases, and cancer, including CRC. Obesity may lead to adipose dysfunction and increased
expression of proinflammatory cytokines. In the tumor microenvironments, there are many
inflammatory cells and cytokines, which can stimulate cell proliferation, decrease cell apoptosis,
and promote cancer metastasis. Therefore, it is believed that chronic inflammation is a central
component of tumor development, progression, and metastasis. Besides inflammation, obesity
associated dysregulated metabolisms, such as insulin resistance, hyperglycemia, and
dyslilidemia, are also involved in obesity associated tumor incidence and growth.

2.2.1 Adipose tissue inflammation
Recently, adipose tissue is recognized as the body’s largest endocrine organ. Adipose tissue
can secret many kind of cytokines and adipokines. When the energy consumed excesses than
needs, because of the needs of energy storage, adipose tissue has to remodel to accommodate
this need. The adipose tissue remodeling processes include: adipose tissue expansion
(increased adipocyte size and/or number); recruitment of proinflammatory immune cells;
remodeling of the vasculature and the extracellular matrix. Subsequently, the above remodeling
processes can lead to significant changes in the composition of the adipose tissue, and
decreasing the number of the anti-inflammatory Treg and TH2 cells, while increasing the
numbers of pro-inflammatory TH1 and CD8+ T cells.

2.2.2 Mechanisms of inflammatory responses in obese adipose tissue
Adipocytes play a pivotal role in adipose inflammation. Adipocytes express adiponectin and
leptin. After secreted by adipocytes, leptin induces inflammatory response in obesity. However,
adiponectin has anti-inflammatory effects. Circulating levels of adiponectin decrease associated
6

with increasing visceral obesity. Leptin plays a key role in inducing adipose proinflammatory
processes (Deng, Lyon et al. 2013). Leptin stimulates the secretion of several cytokines, such
as TNF-α, IL-1, IL-6, and IL-12. Leptin also increases reactive oxygen species (ROS) production
and the secretion of leukotriene B4, cyclooxygenase 2 (COX2), and nitric oxide (Carbone, La
Rocca et al. 2012). Leptin also can increase T cell proliferation and TH1 cell polarization and
inhibits Treg proliferation, which is an important negative regulator of adipose inflammation.
During obesity, immune cells is increased in adipose tissue, which is one of the characteristics
of obesity and a major component of adipose inflammation linked to systemic complications of
obesity (Xu, Barnes et al. 2003). Therefore, drugs or bioactive compounds that promote
macrophages toward M2, might have the potential to inhibit adipose tissue inflammation and
systemic complications of obesity (Han, Jung et al. 2013).

2.2.3 Adipose tissue and the tumor microenvironment
Tumor microenvironment (TME) plays a crucial role in the initiation and progression of CRC.
The TME are composed of fibroblasts, adipocytes, cytokines, inflammatory and immune cells,
blood vessels, and extracellular matrix. The TME usually has increased level of cytokines and
growth factors which can increase antiinflammatory TH2 and Tregs, and decrease
proinflammatory TH1 cells. It is believed that TME can prevent carcinogenesis in normal
conditions. However, TME can also be modified and then become promoting progression and
metastasis (Chen, Zhuang et al. 2015). Cancer cells, immune cells, and inflamed adipose tissue
can alter TME, and subsequently promote tumor progression. For instance, inflammatory
environment can induce mutations and proliferation of these cells, activate transcription factors
such as STAT3, NF-kB, and activator protein 1; increase nutrients supply by angiogenesis.
Tumor-promoting cytokines are proinflammatory cytokines, such as TNF-α, IL-1β. TNF-α, IL-1β
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can induce epithelial-mesenchymal transition (EMT), and tumor metastasis into lymphatics and
remote organs.

2.2.4 Obesity and CRC
2.2.4.1 Epidemiology of Obesity associated CRC
It is estimated that around 11% of CRC cases are caused by overweight and obesity.
Epidemiological studies have shown that obesity is associated with a 30-70% increased risk of
cancer. Specifically, it is suggested that visceral adiposity are more closely associated with CRC
(Donohoe, O'Farrell et al. 2014). Beside the role of obesity in CRC incidence, obesity is also
associated with poor prognosis of CRC. Inflammatory bowel diseases independently increase
CRC risk, highlighting the role of inflammation in CRC development (Farraye, Odze et al. 2010;
Khandekar, Cohen et al. 2011). Therefore, it is well accepted that obesity and chronic
inflammation play as pivotal role in CRC initiation, tumor progression, and metastasis.

2.2.4.2 Obesity and cancer initiation
Epidemiological and experimental data suggest that leptin and adiponectin are associated with
CRC risk(Drew 2012). Specially, increased leptin expression is associated with increased risk of
CRC, whereas, decreased adiponectin is associated with CRC pathogenesis (Tutino,
Notarnicola et al. 2011; Hebbard and Ranscht 2014). Hardwick et al, suggested that high fat diet
(HFD) induced CRC carcinogenesis is mediated through increased serum leptin levels
(Hardwick, Van Den Brink et al. 2001). The possible explanation is that, in lean adipose tissue,
adiponectin suppresses secretion of adipose-derived proinflammatory cytokines such as IL-6,
however, in obese adipose tissue, leptin increases production of TNF-α, IL-6, and IL-12, which
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can promote CRC incidence. In consistent with this explanation, adiponectin knockout mice
exhibits high level of proinflammatory cytokines (including IL-6, IL-1β, and TNF-α) and develops
larger size of CRC. Among those proinflammatory cytokines, TNF-α may activate transcription
factor NF-kB, which can increase secretion of proangiogenic factors and growth factors.

2.3 Tumor necrosis factor-α
Tumor necrosis factor-α (TNF-α), a glycoprotein, was reported that it can induce necrosis of
cancer without injury to other surrounding normal tissues (Carswell, Old et al. 1975). In 1984,
TNF-α gene was cloned, and recombinant human TNF-α could induce necrosis of cancer in
mice, which seems have great promise in the treatment of cancer (Pennica, Nedwin et al.
1984).

2.3.1 TNF-α Signaling
TNF-α is mostly secreted by the activated inflammatory cells, such as macrophages, mast cells,
and T lymphocyte, but other cell types including cancer cells also secret TNF-α. TNF-α is first
synthesized as a type II transmembrane protein (tmTNF-α) which contains an external Cterminus and cytoplasmic N-terminus (Figure 2.2). The cleavage of the extracellular domain of
tmTNF-α by TNF-α-converting enzyme (TACE, a matrix metalloprotease) leads to the
production of soluble TNF-α (sTNF-α).

9

Figure 2.2. Diagram showing tmTNF-α (membrane TNF-α) cleavage by TACE into sTNF-α
(soluble TNF-α).

tmTNF-α and sTNF-α are both active. TNF-α can bind with two different receptors, TNF-α
receptor 1 (TNFR1) and TNF-α receptor 2 (TNFR2). Both TNFR1 and TNFR2 receptors do not
have intrinsic enzyme activity and therefore they need cytosolic adaptor proteins to transduce
intracellular signals. TNF-α can activate pathways that control three distinct cellular responses:
cell survival and proliferation; transcription of pro-inflammatroy genes; and cell death (Waters,
Pober et al. 2013). TNFR1 activation can control the following signaling pathways: the nuclear
factor-kappa B (NF-κB), the extracellular signal-regulated kinase (ERK), the c-Jun N-terminal
Kinase (JNK), the p38 mitogen-activated protein kinase (p38 MAPK), the 1 acidic
sphingomyelinase (A-SMase), and the neutral sphingomyelinase (N-SMase) Pathways (Olmos
and Llado 2014).
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After binding with TNF-α, TNFR1 will do a conformational change in its cytoplasmic portion,
which will assemble the TNFR complex 1, which include TNF receptor-associated death domain
(TRADD), receptor-interacting protein 1 (RIP1; also known as RIPK1), cellular inhibitor of
apoptosis proteins (cIAPs), TNF receptor-associated factor 2 (TRAF2) and TRAF5(Song, Zhou
et al. 2016). Compared to the signaling pathways initiated by TNFR1, TNFR2 is the preferential
receptor for tmTNF-α and is less characterized. TNFR2 can activate IKK, leading to nuclear
translocation of NF-κB through a pathway similar to TNFR1(Sun 2011). Distinct signaling
pathways upon TNFR2 binding have also been studied (Rodriguez, Cabal-Hierro et al. 2011).
Previous study have shown that TNFR2 can potentiate the apoptotic response to TNF-α,
suggesting that TNFR2 may function as a high-affinity trap of TNF-α that delivers the ligand
signal to TNFR1 (Richter, Messerschmidt et al. 2012).

After binding with TNF-α, TNFR1 has a conformational change, leading the assembly of the
TNFR complex 1. TNFR complex 1 include TNF receptor-associated death domain (TRADD),
receptor-interacting protein 1 (RIP1; also known as RIPK1), cellular inhibitor of apoptosis
proteins (cIAPs), TNF receptor-associated factor 2 (TRAF2) and TRAF5 (Song, Zhou et al.
2016). Unlike TNFR1, TNFR2 are more likely bind to tmTNF-α and are less studied. TNFR2 can
activate IKK, resulting in nuclear translocation of NF-κB (Sun 2011). Previous study suggested
that TNFR2 can potentiate the apoptotic response to TNF-α, suggesting that TNFR2 may
function as a high-affinity trap of TNF-α that delivers the ligand signal to TNFR1 (Richter,
Messerschmidt et al. 2012).

2.3.2 TNF-α response in tumors
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At first, TNF-α was recognized as a promising strategy for cancer treatment. However, it has
also been shown that TNF-α can be derived from many tumor cells (Zins, Abraham et al. 2007;
Al-Lamki, Sadler et al. 2010; Aggarwal, Gupta et al. 2012; Landskron, De la Fuente et al. 2014).
As a result, the role of TNF-α in tumor survival, migration, and invasion, are more and more
appreciated.

2.3.2.1 TNF-α and cancer cell death
The binding of TNF-a to TNFR1 leads to the assembles signaling complex I, which recruits Fasassociated death domain protein (FADD), forming a complex DISC (also known as complex 2)
(Micheau and Tschopp 2003). Caspases-8 and caspases-10, which are initiator caspases, are
activated within the DISC complex (Parrish, Freel et al. 2013). Activated caspases-8 and 10 can
directly cleave and activate effector caspases, such as caspases 3 and 6. Effector caspase can
then cleave nuclear lamins leading to the nuclear fragmentation. It is well known that inhibition
of caspases is capable of protecting cells from apoptotic cell death. In contrast, necrosis has a
feature of a gain in cell volume, swelling of organelles, and irreversible plasma membrane
damage (Festjens, Vanden Berghe et al. 2006). Necroptosis can be initiated by the TNF-a DISC
through RIPK-1-mediated recruitment and activation of the structurally related protein RIPK-3
(Hitomi, Christofferson et al. 2008; Bonnet, Preukschat et al. 2011; Welz, Wullaert et al. 2011).
Interestingly, even absence of FADD or pro-caspase 8, TNF-α can also induce cell death.
Another mechanism of how TNF-α exerts antitumor effects is through induction of autophagy,
which can be a precursor to both apoptotic and necrotic cell death (Figure 2.3 ).
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Figure 2.3. TNF-α induces tumor apoptosis and necroptosis via distinct signaling pathways.

2.3.2.2 TNF-α and cancer-related inflammation
TNF-α, being secreted in a setting such as chronic inflammation and infections, can increase
the risk of cancer. For example, Helicobacter pylori is an important risk factor gastric cancer;
inflammatory bowel disease increases the risk of colonic cancer (Wroblewski, Peek et al. 2010;
Kim and Chang 2014). TNF-α might speed up cancer cell growth by modulating leukocytes,
including T cells, B cells and/or tumor-associated macrophages (TAMs). TNF-α can increase
TNFR1-dependent IL-17 production, subsequently, myeloid cell was recruited into the tumor
microenvironment and tumor growth was accelerated (Charles, Kulbe et al. 2009). TNF-α also
plays an important role in tumor angiogenesis by inducing VEGF production. B cells are
important effector cells for TNF-α-mediated carcinogenesis and produce a significant amount of
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TNF-α. TNF-α may modulate the activity of regulatory B cells through repressing anti-tumor
immunity (Schioppa, Moore et al. 2011).

2.3.2.3 TNF-α and cell proliferation, survival, and angiogenesis
TNF-α stimulates proliferation, invasion, survival, migration, and angiogenesis via TNFR1. In
addition, TNF-α binding with TNFR2 also activates the PI3K/Akt pathway leading to cell
migration and proliferation (Yang, Wang et al. 2018). In vascular endothelial cells, TNF-α may
activate epithelial and endothelial tyrosine kinase (Etk) and vascular endothelial growth factor
receptor 2 (VEGFR2), leading to enhanced angiogenesis (Pan, An et al. 2002; Zhang, Xu et al.
2003). In renal cell carcinoma, TNF-α may increase tumor progression by acting selectively
through a TNF-α/Etk/VEGFR2 pathway. (Al-Lamki, Sadler et al. 2010).

2.3.3 TNF-α as a therapy for cancer.
Although TNF-α can be used to treat cancer, it has several side effects such as fever, septic
shock, and cachexia (Locksley, Killeen et al. 2001). It is estimated that the maximum tolerated
dose (MTD) that can be used systemically in clinic is 10-fold lower than the dose inducing
cancer cell death (Schiller, Storer et al. 1991; Skillings, Wierzbicki et al. 1992). Due to those
side effects, the clinical application of TNF-α was restricted to the isolated limb perfusion (ILP)
setting for soft tissue sarcoma (STS) and melanoma in-transit metastases confined to the limb.
It is reported that the combination of TNF-α and melphalan may induce regression of
unresectable metastases from colorectal cancer. TNF-α is believed to target the tumor
vasculature, by decreasing Alpha-v-beta-3 integrin (Ruegg, Yilmaz et al. 1998; Grunhagen, de
Wilt et al. 2006). It is suggested that TNF-α can increase tumor blood vessel permeability, thus
leading to increased tissue concentration of chemotherapy and destroying the tumor
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vasculature (Seynhaeve, Hoving et al. 2007). TNF-α may also promote tumor necrosis by
inducing coagulant effect, in which TNF-α can increase fibrin deposition and thrombus formation
in the cancer vasculature (Zhang, Deng et al. 1994; Zhang, Deng et al. 1996).

2.3.4 TNF-α as a target for cancer.
Komori et al first reported that TNF-α may be involved in activation of oncogene and DNA
damage(Komori, Yatsunami et al. 1993). TNF-α can increase the carcinogenesis by stimulating
clonal evolution (Li, Sejas et al. 2007). In addition, TNF-α can also contribute to carcinogenesis
by inducing DNA damage in cancer cells, and normal lung epithelial cells(Babbar and Casero
2006; Yan, Wang et al. 2006). Furthermore, clinical trials suggested that neutralizing TNF-α
might be beneficial in cancer patients. In a phase I study, the anti-TNF antibody infliximab can
stabilize previously progressing advanced cancer in 7 of 41 patients (Brown, Charles et al.
2008). In a phase II study, TNF-α antagonist etanercept, a soluble TNFR2 fusion protein that
binds and neutralizes TNF-α, can also stabilize diseases in 6 of 30 progressing ovarian cancer
patients(Madhusudan, Foster et al. 2004), and in 14 of 30 renal cell cancer patients (Harrison,
Obermueller et al. 2007). However, the molecular mechanisms of action of anti-TNF in cancer
patients are still unclear. It is suggested that TNF-α antagonists inhibit cytokine and chemokine
production, recruitment of inflammatory cells, angiogenesis and extracellular matrix degradation
(Tracey, Klareskog et al. 2008). Some of the mouse model experiments demonstrated a role for
TNF antagonists in cancer prevention. Previous studies also have shown that traditional medical
herbal and the polyphenols present in tea inhibit TNF-α release (Fujiki, Suganuma et al. 2003).
Recent studies suggested that tumor microenvironment levels of sTNF-R2 may represent a
factor of poor prognosis and in epithelial ovarian cancer (Nomelini, Borges Junior et al. 2018).
Given the fact that TNF-α plays an important role in regulating innate immunity, TNF-α
antagonists might increase risk of infection. Therefore, many patients with rheumatoid arthritis
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or other chronic inflammatory diseases are recruited in the clinic trials for studying cancer
incidence during TNF-α antagonist treatment (Table 1).

Study Design

Diseases

Treatment

Duration

Results

Cohort study

Rheumatoid

TNF inhibitor

13 years

Not increase risk of

Arthritis

and rituximab

cancer(Silva-Fernandez, Lunt
et al. 2016)

Cohort study

Inflammatory

TNF inhibitor

3.7 years

bowel disease

Not increase risk of cancer
(Nyboe Andersen, Pasternak
et al. 2014).

Cohort study

Rheumatoid

TNF inhibitor

9.4 years

Arthritis

Not increase risk of
cancer(Raaschou, Frisell et al.
2015)

Cohort study

Crohn’s disease

Vedolizumab

54 weeks

cancer(Amiot, Serrero et al.

Ulcerative

2017)

colitis
Cohort study

Rheumatoid

Not increase risk of

TNF inhibitor

5 years

Arthritis

Not increase risk of
cancer(Mercer, Lunt et al.
2015)

Clinical trial

Advanced

Infliximab

50 weeks

caner

No evidence of disease
acceleration(Brown, Charles et
al. 2008)
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Cohort study

Rheumatoid

TNF inhibitor

10 years

Arthritis

Not increase risk of
cancer(Phillips, Zeringue et al.
2015)

Cohort study

Rheumatoid

TNF inhibitor

Arthritis

14 years

Reduced risk of cancer(Wu,
Chen et al. 2014)

Table 1. Effects of TNF inhibitor on risk of cancer.

2.4 Vitamin D
Vitamin D is a group of steroids with a broken ring: secosteroids. Vitamin D is grouped into two
major physiologically relevant forms, ergocalciferol (vitamin D2), which is mostly derived from
plants, and cholecalciferol (vitamin D3), which is photosynthesized in the skin of animal by the
action of UVB on 7-dehydrocholesterol. The most major source of vitamin D is obtained by
cutaneous production from UVB. Sincere the production of vitamin D can be interrupted by
latitude, season, ageing, skin pigmentation, it is crucial to get enough vitamin D from diet to
maintain a satisfied vitamin D level (Bikle 2014). In the United States, the main dietary source of
vitamin D is from dietary products and some fortified foods such as breakfast cereals, soy
beverages, and orange juice. Natural sources of vitamin D include fish, and egg yolks.

2.4.1 Synthesis and Metabolism of Vitamin D
Vitamin D3 can be obtained from dairy products and fish oils or be photosynthesized in the skin
by the action of sun exposure on 7-dehydrocholesterol. As shown in Figure 2.4, synthesis of
vitamin D depends on the doses of UVB. Since sunscreen, skin color can block sun exposure,
sunscreen and skin color decrease the production of vitamin D (Matsuoka, Wortsman et al.
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1992). Vitamin D is transported to the liver in the blood vessels by binding to vitamin D-binding
protein (DBP). In the liver, vitamin D is converted into 25-hydroxyviatmin D [25(OH)D3] by the
25-hydroxylase (CYP27A1), resulting to 25(OH)D3. The 25(OH)D3 is then hydroxylated in the
kidney by 1-hydroxylase (CYP27B1, 1-OHase), yielding the active form of vitamin D,
1,25(OH)2D3. 1,25(OH)2D3 has different effects on various target tissues. In the kidney, 24
hydroxylase (CYP24) also can hydroxylate 25(OH) D3 and 1,25(OH)2 D3, resulting 24,25(OH)2
D3, 1,24, 25(OH)3 D3. Compared to active 1,25(OH)2 D3, 24,25(OH)2 D3 and 1,24, 25(OH)3 D3
are relatively inactive (Bikle 2014). Calcitriol [1,25(OH)2 D3] exerts multiple cancer prevention
effects on various malignant cells and animal models.

Figure 2.4. Vitamin D synthesis and metabolism
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2.4.2 Mechanisms of the anti-cancer effects of calcitriol
As shown in Figure 2.5, several molecular mechanisms are involved in the cancer prevention
effects of calcitriol. It is suggested that the cancer prevention effects of calcitriol is obtained by
binding to nuclear vitamin D receptor (VDR), mostly via genomic actions (Deeb, Trump et al.
2007; Mikhak, Hunter et al. 2007; Ingraham, Bragdon et al. 2008; Li, Li et al. 2017).

Figure 2.5. Mechanisms underlying the anticancer effects of calcitriol

2.4.2.1 Regulation of cell cycle and apoptosis
Calcitriol has anti-proliferative effect in many cancer cells by modifying cell cycle (Sarkar,
Hewison et al. 2016), inducing apoptosis (Dou, Ng et al. 2016). Specifically, calcitriol decreases
the proliferation of cancer cells through increasing the production of cyclin dependent kinase
(CDK) inhibitors p21 and p27, and decreasing CDK activity (Flores, Wang et al. 2010). In the
meanwhile, the combination of calcitriol and conventional therapies might also downregulate the
expression and activity of important signaling pathways which can regulate the cell cycle.
(Segovia-Mendoza, Diaz et al. 2017).

2.4.2.2 Enhancement of differentiation
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Besides inhibition of proliferation, calcitriol also has the ability of inducing the differentiation of a
variety of cancer cells, including CRC cells (Diaz, Diaz-Munoz et al. 2015). In addition, calcitriol
can induce terminal differentiation of human myeloid leukemia cells into monocytes and
macrophages (Vasylyeva, Chen et al. 2005). Previous study also has shown that calcitriol might
be able to upregulate the expression of myoepithelial markers in SUM159 mammospheres
(Shan, Wahler et al. 2017).

2.4.2.3 Modulation of angiogenesis
Calcitriol can decrease the angiogenesis of new blood vessel formation in cancer
microenvironment. For example, in Vdr-null mice, there are increased expression of proangiogenic factors such as Hypoxia-inducible factor 1 alpha (HIF 1α), vascular endothelial
growth factor (VEGF), angiopoietin 1, platelet-derived growth factor (PDGF) in tumors (Chung,
Han et al. 2009). In addition, Calcitriol can inhibit cyclooxygenase-2 (COX-2) induced production
of prostaglandin E2 (PGE2), which can induce angiogenesis by secreting HIF 1α in cancer cells
(Fukuda, Kelly et al. 2003).

2.4.2.4 Anti-inflammation
As I discussed above, a large amount of evidence suggests that chronic inflammation plays an
important role in cancer development and progression (Koul, Kumar et al. 2010; Sfanos,
Hempel et al. 2014; Crusz and Balkwill 2015). Previous studies have shown that calcitriol
exhibits anti-inflammatory actions in several cancers (Krishnan and Feldman 2011). Calcitriol
decreases the expression of COX2, PGE2, and other inflammatory cytokines in prostate cancer
cells (Moreno, Krishnan et al. 2005) and ovarian cancer cell lines (Thill, Woeste et al. 2015).
This may be because calcitriol can alter several pro-carcinogenic inflammatory pathways, such
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as NF-κB(Bao, Yao et al. 2006; Cohen-Lahav, Shany et al. 2006), and p38 stress kinase
pathway(Nonn, Peng et al. 2006).

2.4.3 Vitamin D in clinical trials
In WHI clinical trial, supplementation with a small amount of vitamin D3 (400 IU per day) and
calcium (1 g per day) did not show a CRC prevention effect. (Wactawski-Wende, Kotchen et al.
2006). One limitation of this study is that the low dose of vitamin D (400 IU per day) may not
significantly raise the serum 25(OH)D levels (Tella, Gallagher et al. 2014). Reanalyzing the WHI
clinical trial, Ding et al found that vitamin D and calcium supplementation may exert CRCs
cancer prevention effects in postmenopausal women who do not use estrogen therapy (Ding,
Mehta et al. 2008). Vahedpoor et al found that after 6 months of vitamin D supplementation,
patients with cervical intraepithelial neoplasia grade 1 have shown cancer regression and
improved metabolic status(Vahedpoor, Jamilian et al. 2017). However, in a RCT study of
healthy postmenopausal women, vitamin D and calcium supplementation did not decrease the
cancer risk after 4 years of supplementation(Lappe, Watson et al. 2017). One possible
explanation of negative results is that the control participants have a higher baseline serum
vitamin D level (32.8 ng/ml) compared with the US population. It is estimated that 75-80% the
US adult population had serum vitamin D levels less than 30 ng/ml, and approximately 30% had
vitamin D levels below 20 ng/ml(Yetley 2008). In patients with early recurrent prostate cancer,
calcitriol therapy decreased the rate of rise of prostate specific antigen (PSA) (Gross, Stamey et
al. 1998).

2.5 Sulforaphane
2.5.1 Sulforaphane Bioavailability
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Sulforaphane (SFN) [1-isothiocyanato-4-(methylsulfinyl)butane], a isothiocyanate, has been
reported that it has chemopreventive property. SFN contains an isothiocyanate group (−N = C =
S) and a methylsulfonyl side chain (R-(S-O)-R). (Figure 2.6) SFN is a plant-origin isothiocyanate
organosulfur compounds, which has been extensively studied. It has been suggested that SFN
has many biological effects including cancer prevention(Amjad, Parikh et al. 2015), and
inflammation prevention (Greaney, Maier et al. 2016).

Figure 2.6. The molecular structure of sulforaphane in broccoli

Besides its well known cancer prevention effect, SFN is known to possess anti-inflammatory
property(Liu and Talalay 2013). Nuclear factor kappa B (NFkB) plays a pivotal role in the
inflammatory conditions (Tak and Firestein 2001). It is well known that NFkB activation can lead
to the up-regulation of oncogenes and proinflammatory cytokines in the colon cancer and
prostate cancer. It has been reported that NFkB pathway is highly active in patients with solid
cancers such as colon, prostate, breast cancers(Aggarwal and Gehlot 2009). Further studies
have suggested that SFN formed adducts with cysteine residues in the extracellular domain of
TLR4, resulting in the inhibition of NFκB mediated signaling pathway.

2.5.2 Anticancer Activity of Sulforaphane
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Epigenetic alterations play a pivotal role in the cancer prevention effects of SFN (Golson and
Kaestner 2017). Compared with genetic alterations, epigenetic changes are reversible. There
are two major types of modifications in epigenetic alterations: histone modifications, which are
flexible, and DNA methylation, which are generally stable (Kouzarides 2007). Histone
acetylation reduces the positive charge of the histone proteins, leading to a reduced affinity for
DNA and resulting in an open chromatin structure that easies the access of transcription factors
to specific gene loci. In the mean time, histone deacetylases (HDACs) can remove the acetyl
group (Figure 2.7). It is well known that overexpression and / or over activity of HDAC are
characteristics of cancer, which can lead to a reduced transcription of genes responsible for
apoptosis and cell cycle arrest (Fraga, Ballestar et al. 2005).

Figure 2.7. Modulation of chromatin conformation and transcriptional status by acetylation of
lysine tails in histone core proteins. HDAC, histone deacetylase; HAT, histone acetyltransferase.
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SFN can act as an HDAC inhibitor, resulting in cancer cell cycle arrest and apoptosis (Ho,
Clarke et al. 2009). Myz ak et al., first reported that SFN can increase TOPflash reporter activity
without changing expression of β-catenin, indicating that SFN alterd the activity of HDAC
(Myzak, Karplus et al. 2004). In human embryonic kidney 293 cells, SFN dose-dependently
decrease HDAC activity (Myzak, Karplus et al. 2004). It is suggested that 15 µM SFN can
significantly inhibit HDAC activity in three prostate epithelial cell lines (BPH-1, LNCap, and PC3)
(Myzak, Hardin et al. 2006). Another study reported that after a single oral dose of SFN, SFN
significant inhibited HDAC activity in the colonic mucosa and suppressed tumor development in
APCmin mice (Myzak, Dashwood et al. 2006). In HCT116 colon cancer cells, 15 µM SFN can
significantly inhibit the activity of HDAC1, HDAC2, HDAC3, and HDAC8 after 36 h of treatment
(Rajendran, Delage et al. 2011).

Previous studies have shown that DNA methylation pattern is changed during cancer initiation
and progression. The changes include global and site specific DNA hypomethylation as well as
gene specific promoter hypermethylation (Portela and Esteller 2010; Baylin and Jones 2011).
Hypomethylation of the promoter of oncogenes can increase their expression, while, DNA
hypermethylation may lead to the inhibition of genes involved in cell cycle regulation and
apoptosis. Regulation of DNA methylation patterns are mediated by DNA methyltransferases
(DNMTs). DNMTs are overexpressed in leukemic, gastric, lung, and prostate cancer (Mizuno,
Chijiwa et al. 2001; Etoh, Kanai et al. 2004; Morey Kinney, Smiraglia et al. 2008; Lin, Wu et al.
2010).
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Previous studies have shown that the expression of DNMT1 and DNMT3a was inhibited by SFN
treatment in human breast cancer cells and prostate cancer cell lines(Meeran, Patel et al. 2010;
Hsu, Wong et al. 2011). Treatment with SFN for 24 h can decrease global methylation in LNCap
cells(Kobayashi, Nakamura et al. 2009). SFN treatment can decrease methylated CpG sites in
the promoter region of cyclin D2 in prostate cancer cells. In addition, SFN treatment can also
decrease methylation at the binding site of the c-Myc transcription factor. However, SFN
treatment failed to alter abnormal methylation patterns in critical genes involved in colon
carcinogenesis in colon cancer cells (Barrera, Johnson et al. 2013).

2.5.3 Sulforaphane in Human Studies
A number of clinical trials are conducted to determine the cancer prevention effects of SFN.
Kensler et al have shown that the level of SFN metabolites is inversely associated with cancer
markers in resident of Qidong who have a high risk of hepatocellular carcinoma (Kensler, Chen
et al. 2005). Another study shows that consumption of 400 µM glucoraphanin may increase the
excretion of airborne pollutants (Kensler, Ng et al. 2012). Kirsh et al reported that consumption
of cruciferous vegetables especially broccoli is associated with a significantly decreased risk of
prostate cancer (Kirsh, Peters et al. 2007). However, in another clinic study, treatment with 200
µM per day of SFN-rich extracts did not lead to ≥ 50% PSA declines in the majority of patients
(Alumkal, Slottke et al. 2015).

2.6 Butyrate
2.6.1 Background
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Butyrate is a four-carbon short-chain fatty acid, which can be produced by anaerobic bacteria
fermentation of dietary fiber in the colon (Figure 2.8). 2 metabolic pathways are involved in the
production of butyrate. In the first pathway, butyryl-CoA is phosphorylated and converted to
butyrate by butyrate kinase (Louis and Flint 2017). In the other pathway, the butyrylCoA:acetate CoAtransferase transfers the CoA moiety of butyryl-CoA to acetate, resulting to the
production of butyrate and acetyl-CoA (Trachsel, Bayles et al. 2016). Butyrate is the major
energy source for colonocytes (Slavin 2013; Conlon and Bird 2014).

Figure 2.8. Butyrate Chemical Structure

Butyrate are absorbed across the apical membrane of the colonocytes by both diffusion and
short-chain fatty acid (SCFA) transporter. There are two SCFA transporters, monocarboxylate
transporter (MCT) isoform 1 (MCT1), and solute carrier (SLC) family 5 member 8 (SLC5A8)
(Counillon, Bouret et al. 2016). Orphan G protein-coupled receptor 41 (GPR41) and GPR43 are
the receptors for SCFA. GPR41 and GPR43 are also known as FFAR3 and FFAR2 respectively
(Brown, Goldsworthy et al. 2003). Butyrate preferentially binds to GPR41 over GPR43. GPR41
is universally expressed in a variety of tissues including adipose tissue, pancreas, spleen, lymph
nodes, bone marrow, and peripheral blood mononuclear cells including monocytes(Brown,
Goldsworthy et al. 2003; Le Poul, Loison et al. 2003). GPR43 also expressed in colon cells, and
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adipocytes, and the highest expression of GPR43 was found in immune cells such as
monocytes and neutrophils (Nilsson, Kotarsky et al. 2003).

2.6.2 Butyrate and Anti-inflammation
Studies have shown that butyrate is a promising anti-inflammatory agent. Butyrate can inhibit
the secretion of the proinflammatory cytokines such as IFN-γ, TNF-α, IL-1β, IL-6, and IL-8,
whereas enhance the production of the anti-inflammatory cytokines IL-10 and TGF-β. It is
suggested that the molecular mechanisms underlying the inhibition of inflammation by butyrate
are partially due to inhibition of NF-κB. Further studies suggest that butyrate suppresses the NFκB signaling pathway activation by rescuing the redox machinery and controlling reactive
oxygen species (Russo, Luciani et al. 2012). Activation of PPAR-γ by butyrate is another
possible mechanism of anti-inflammatory activity of butyrate. Previous studies have suggested
that PPAR-γ is a member of the nuclear receptors, and activation of PPAR-γ can exert antiinflammatory effects (Mattace Raso, Simeoli et al. 2013). Butyrate may inhibit signaling of IFN-γ,
which plays a crucial role in inflammation-associated CRC development (Schwab, Reynders et
al. 2007; Zimmerman, Singh et al. 2012).

2.6.3 Butyrate and CRC
Epidemiological and animal studies have shown that dietary fiber can inhibit CRC incidence
(Baena and Salinas 2015; Encarnacao, Abrantes et al. 2015). One of the explanations of CRC
prevention effect of butyrate is that bacterial fermentation convert resistant starch to SCFA
(Song, Garrett et al. 2015). Among SCFA, butyrate plays a pivotal role in the
prevention/inhibition of colon carcinogenesis (Manning and Gibson 2004). Butyrate can induce
colon cancer cell differentiation and apoptosis, and inhibit colon cancer cell
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differentiation(Goncalves, Araujo et al. 2011). Similarly, several animal studies also suggested a
protective effect of butyrate on CRC carcinogenesis (D'Argenio, Cosenza et al. 1996; Kameue,
Tsukahara et al. 2004; Lu, Nakanishi et al. 2013). Human studies also found an inverse
relationship between the levels of butyrate in the human colon and the incidence of CRC
(Bingham, Day et al. 2003). The risk of developing tumors are higher in the distal colon where
the concentration of butyrate is lower, implicating butyrate has CRC prevention effect
(Mortensen, Holtug et al. 1988).

It seems that the underlying mechanisms of cancer prevention effect of butyrate involve
regulation of gene expression, which due to its capacity of HDAC inhibition. Acting as a HDAC
inhibitor, butyrate can result in hyperacetylation of histones. Beside HDAC, it is likely that
butyrate has other targets, such as DNA methylation (Dehaan, Gevers et al. 1986), histone
methylation (Pesavento, Yang et al. 2008), hyperacetylation of nonhistone proteins (White,
Mulligan et al. 2006), inhibition of histone phosphorylation(Mathew, Ranganna et al. 2010),
regulation of expression of micro-RNAs (miRNA) (Hu, Dong et al. 2011), and modulation of
intracellular kinase signaling (Basson and Hong 1998). In addition, butyrate can also alter
immune response in the colon and moderate gut bacteria community to maintain colonic
mucosa homeostasis(Lupton 2004). The cancer prevention effect of butyrate depends on its
intracellular concentration (Mariadason 2008; Ashktorab, Belgrave et al. 2009).

2.7 Wnt pathway
The Wnts, a group of nineteen secreted glycoproteins , which is composed of approximately
300 amino acids. The Wnts can activate many signaling pathways, including the canonical
Wnt/b-catenin pathway, Wnt/Ca2+ pathway, and the Wnt/polarity pathway(Prakash and
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Swaminathan 2015). The Wnt proteins are approximately 40 kDa in size. The Wnt signaling
pathway is highly conserved and plays a central role in regulating development and stemness.
Aberrant Wnt signaling plays an important role in the initiation of many cancers. Constitutively
active Wnt signaling is a driver of CRCs progression.

2.7.1 Canonical and non-canonical Wnt signaling
The Wnt signaling pathway is divided into canonical (b-catenin dependent) and non-canonical
(b-catenin independent) pathways. The characteristics of the canonical Wnt pathway are the
accumulation of b-catenin in the cytoplasm, and its subsequent translocation to the nucleus.
When the Wnt ligands is absent, cytoplasmic b-catenin is phosphorylated by a degradation
complex, which is composed of the tumor suppressor adenomatous polyposis coli (APC), the
scaffolding protein AXIN and two kinases CK1 (casein kinase 1) and GSK3b (glycogen
synthase kinase 3b) (Figure 2.9). b-TrCP, a ubiquitin ligase, then recognized phosphorylated bcatenin, therefore, b-catenin is ubiquinated and targeted for degradation by the
proteasome(Tabatabai, Linhares et al. 2017). Wnt ligands first bind to Frizzled receptors as well
as LRP5/6 co-receptors, which can induces dishevelled (DVL) phosphorylation, which
subsequently recruits Axin and destruction complex to the cell membrane. Without destruction
complex, b-catenin accumulated in the cytoplasmic and subsequent enter nucleus. In the
nucleus, b-catenin can bind to the TCF/LEF (T-cell factor/lymphoid enhancer factor)
transcription factors and recruit the transcriptional Kat3 co-activatiors p300 and CBP (CREBbinding protein) to initiate the transcription of Wnt target genes(Duchartre, Kim et al. 2016).
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Figure 2.9. Canonical Wnt Pathway. A. Wnt off. When Wnt protein is absent, β-catenin is
constantly degraded by the destruction complex which includes Axin, APC, Gsk3, and CK1. The
destruction complex targets β-catenin for ubiquitylation (Ub) and subsequently degraded by
proteasome. B. W0nt on. The binding of Wnt protein to the Frizzled/Lrp5/6 receptors resulting in
the phosphorylation of disheveled (Dvl). Activated Dvl then recruits Axin, which can inhibit the
destruction complex, leading to the accumulation of β-catenin in the cytoplasma, which then
enters into the nucleus where it can bind to TCF/LEF to initiate transcription.
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2.7.2 Wnt signaling and cancer
Wnt signaling is crucial for intestinal crypts homeostasis and maintenance of intestinal stem
cells (Flanagan, Austin et al. 2018). It is well known that hyperactivation of Wnt pathway is
present in almost all CRC. Wnt signaling plays a pivotal role in CRCs incidence and is the basis
for CRCs tumorigenesis in patients with familial adenomatous polyposis and in Apc mutant mice
model. It is estimated that approximately 92% of sporadic CRCs contain at least one mutation in
Wnt signaling (2012). Loss of APC function is the main driver of CRCs carcinogenesis. Previous
studies have shown that different mutations of APC result in different activity level of canonical
Wnt pathway (Christie, Jorissen et al. 2013). Interestingly, if APC function is restored, colon
adenomas could regress to normal tissue, which suggested that continuous Wnt signaling
alteration is crucial for CRCs maintenance (Dow, O'Rourke et al. 2015). Notably, although
truncated APC is present, Wnt secretion still can modulate the Wnt pathway signaling
(Voloshanenko, Erdmann et al. 2013).

Besides Apc mutation, mutations in the R-spondin/Lgr5/RNF43 are all involved in CRCs
initiation (de Lau, Peng et al. 2014). Interestingly, somatic RNF43 mutations are appeared
mutually exclusive with Apc mutations and exhibits in 19% of total CRCs cases (Giannakis,
Hodis et al. 2014). R-spondin 3 mutations and fusion proteins are occurred in 10% of CRC
cases. Since RNF43 mutant CRCs is dependent on Wnt secrection, RNF43 mutant CRCs is
highly susceptible to Wnt secretion targeted therapy (van de Wetering, Francies et al. 2015).

Chromosomal instability (CIN) is present in 65 - 70% of sporadic CRCs. CIN is involved in loss
of function of Wnt signaling components, particularly APC (Caldwell, Green et al. 2007; Rusan
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and Peifer 2008). Recent study has shown that insufficient basal Wnt/STOP may accelerate
microtubule assembly rates and CIN in CRCs cells, while restore normal assembly rates could
reverse the CIN phenotype (Ertych, Stolz et al. 2014; Stolz, Neufeld et al. 2015).
SNAI2 is a crucial transcriptional factor that plays a pivotal role in epithelial to mesenchymal
transition (EMT). Canonical Wnt signaling pathway can phosphorylate GSK3β and stabilize
SNAI2, leading to increased EMT (Wu, Li et al. 2012). PI3K-Akt signaling inhibition can lead to
accumulation of β-catenin and FOXO3a, resulting in the increased metastasis (Tenbaum,
Ordonez-Moran et al. 2012). It was reported that Fzd2 expression facilitated EMT and cell
migration by Fyn and Stat3. In a xenograft mouse model of colon cancer, Fzd2 inhibition leads
to reduced tumor growth and metastasis (Gujral, Chan et al. 2014).

2.7.3 Targeting Wnt signaling in CRC
Vantictumab (OMP-18R5) can block WNT-FZD ligand-receptor binding at the membrane, as it is
an antibody that targets the FZD receptors (Gurney, Axelrod et al. 2012). Vantictumab is not on
the Phase 1b to evaluate for the effects of cancer prevention, such as breast, ovarian, and
pancreatic cancers, but not CRCs. Considering the fact that the hyperactivation of Wnt signaling
in CRCs is caused by Apc mutation, it is not surprising that blocking WNT-FZD ligand-receptor
interaction is not a effective treatment for colon cancer. However, CRCs patients who carry
RNF43 mutation are suitable for vantictumab, because ligand-receptor interaction is needed to
initiate the Wnt response (van de Wetering, Francies et al. 2015; Madan, Ke et al. 2016).

The destruction complex degrades β-catenin, therefore, it is an promising target to alter Wnt
pathway. It has been shown that regulation of Axin function via modulating Tankyrase activity
can stabilize the destruction complex. Tankyrase enzymes (TNKS and TNKS2) can destabilize
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the destruction complex by PARsylating Axin and subsequent degradation of Axin. Previous
study suggested that blocking TNKS can inhibit the proliferation of APC-mutant CRC in vitro and
in vivo. In addition, TNKS blockade can synergize with regular chemotherapies and drugs that
inhibit RAS/MAPK and PI3K/AKT pathways (Schoumacher, Hurov et al. 2014; Schoumacher,
Hurov et al. 2014; Wu, Luo et al. 2016). However, more studies need to done to study the safety
and efficacy of TNKS inhibition.

Another strategy is to hamper β-catenin binding with specific transcriptional co-activators. For
example, CCT036477 is small compound that inhibit the binding of β-catenin with CREB binding
protein (CBP) (Emami, Nguyen et al. 2004; Gonsalves, Klein et al. 2011; Jarde, Evans et al.
2013). In vitro studies have shown CCT036477 can dramatically reduce levels of Wnt reporter
gene activity, decrease expression of β-catenin downstream targets, and block binding to the
co-activator TCF. However, little is known about the efficacy of these compounds in vivo.

Anti-CTLA4, anti-PD1 blocking are antibodies that can inhibit immune checkpoint. Interestingly,
a recent study has shown that modulating of Wnt/β-catenin signaling pathway may be involved
in the cancer prevention effect of anti-CTLA4, anti-PD1 antibody(Spranger, Bao et al. 2015). It
maybe because that Wnt/β-catenin signaling inhibition may decrease dendritic cells (DCs)
mediated tumor tolerance (Oderup, LaJevic et al. 2013; Swafford and Manicassamy 2015).
Therefore, poor response to anti-CTLA4, anti-PD1 antibodies might due to high Wnt/β-catenin
signaling activity. Combination Wnt/β-catenin inhibition with immunotherapy might be promising
strategy for CRCs treatment.
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CHAPTER 3
PURPOSE OF THE STUDY
3.1 Research Aims and Hypotheses
3.1.1 Aim 1
The primary objective of the study 1 is to determine if inhibition of TNF-α production is an
effective strategy to delay or prevent high fat diet induced colon cancer onset. To achieve this
goal, we will use the Apc1638N mice, which are heterozygous for a germline mutation in Apc.
Apc1638N mice have a mild tumorigenic phenotype (3 vs 100 tumors) and longer lifespan (>1
years vs 4-6 months) (Heyer, Yang et al. 1999; Taketo 2006).

Chronic inflammation is a central component of obesity associated cancer. TNF-α is a key proinflammatory cytokine which induces other inflammatory mediators. Therefore, many studies
have done to examine the cancer prevention effects of blocking TNF-α on tumorigenesis. It has
been shown that eliminating TNF-α or TNFR can inhibit tumor induction and growth (Moore,
Owens et al. 1999; Suganuma, Okabe et al. 1999).

The Wnt pathway is crucial for maintenance of the intestinal epithelia. Hyperactive Wnt
pathway can induce the incidence and development of colon cancer (Zhan, Rindtorff et al.
2017). It was shown that TNF-α actives Wnt signaling via the induction of GSK3β
phosphorylation (Oguma, Oshima et al. 2008).
We hypothesize that genetic ablation of TNF-α will be an effective strategy to attenuate the
development of colon cancer in mice fed a high fat diet. Moreover, we propose that eliminating
TNF-α induces a decrease of Wnt signaling leading to a reduced risk of colon cancer in mice fed
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a high fat diet. We will evaluate the effects of genetic ablation of TNF-α on obesity associated
intestinal tumorigenesis. QuickPlex SQ 120, a chemiluminescence assay, was used to measure
the inflammatory cytokines. To determine the activation of Wnt pathway and its downstream
genes, we performed Real time PCR and Western blot assay. Immunohistochemical analysis
was used to further confirm the activation of Wnt pathway.

3.1.2 Hypothesis 1
It has been reported that inhibition of TNF-α may reduce cancer risk (Bernert, Sekikawa et al.
2003; Karabela, Kairi et al. 2011). However, it remains to be determined whether inhibition of
TNF-α can decrease high fat diet induced colon cancer. The role of TNF-α in high fat diet
induced colon cancer will be examined in this study using TNF-α-deficient mice crossed with
Apc1638N mice. We hypothesize that ablation of TNF-α decrease the risk of obesity associated
CRCs. To test this hypothesis, Apc1638N mice will be randomly divided into 2 dietary groups, 12
animals / group: LF, a low fat diet (10 cal% fat); HF, a high fat diet (60 kcal% fat). 12 TNF-αdeficient mice crossed with Apc1638N mice will receive a high fat diet (60 kcal% fat). After 16
weeks on diet starting at 4-6 weeks of age, mice were euthanized with CO2. Plasma samples
were collected and stored at -80 °C for analyses of cytokines. Tissue samples were collected
using the methods reported before (Liu, Brooks et al. 2012).

TNF-α is one of the central cytokines in the inflammation. Our working hypothesis is that genetic
ablation of TNF-α may attenuate inflammation in the diet-induced obese mice. To test this
hypothesis, the inflammatory cytokines were measured by a chemiluminescence assay using
the QuickPlex SQ 120 (Meso Scale Diagonostics, Rockville, MD). Inflammation of the colon will
be further confirmed by H&E stained histological sections.
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Based on our previous studies, we have confirmed that high fat diet induced obesity is
associated with a significant increase of TNF-α level in mouse colon, and activation of the Wnt
signaling pathway. Therefore, we hypothesize that tumorigenesis effects of TNF-α is mediated
by a direct activation of Wnt pathway, and genetic ablation of TNF-α might down-regulate Wnt
pathway. We will analyze the effects of genetic ablation of TNF-α on key signaling proteins of
Wnt pathway by immunoblotting analysis. We will measure the levels of phospho-GSK3β
(Ser9), the inactive form of GSK3β, and the dephosphorylated β-catenin (Ser37 or Thr41), the
active form, which are two key molecules in the Wnt pathway. Immunohistochemical analysis
will be utilized to further determine the effect of genetic ablation of TNF-α on the activation of
active β-catenin. Our expectation is that genetic ablation of TNF-α attenuates active β-catenin
and its downstream targets in APC1638N mice.

3.1.3 Aim 2
The study 2 aimed to test a dietary strategy, the supplementation of a high dose of vitamin D
(VD) or its combination with sulforaphane (SFN), to inhibit intestinal inflammation and thereby
obesity-associated tumorigenesis. VD is crucial for a variety of physiological and pathological
processes in the human body. VD also can regulates numerous cellular pathways that affect cell
proliferation, differentiation, and apoptosis, therefore, VD plays an important role in cancer
incidence, prognosis, and mortality (Fleet 2008; Ng 2014). However, studies have shown
conflicting results.

In study 2, we used a high VD (5,000 IU) with a low VD (200 IU) as a control group. The
phytochemical sulforaphane (SFN) is an isothiocyanate derived in cruciferous vegetables and is
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especially high in broccoli and broccoli sprouts. Epidemiologic studies suggest that higher intake
of cruciferous vegetables is associated with low risk of CRC (Wu, Yang et al. 2013). It is
suggested that SFN may act as a histone deacetylase (HDAC) inhibitor activity in human CRC
cell lines (Ho, Clarke et al. 2009). In addition, previous studies have shown that HDAC inhibitors
can sensitize cancer cells to anti-cancer drugs (Regel, Merkl et al. 2012). However, the
combination effects of VD and SFN on high fat diet induced CRCs is not well studied.

3.1.4 Hypothesis 2
We anticipate that VD co-administration with SFN may further inhibit obesity associated colon
cancer. To investigate the effect of VD or VD in combination with SFN in obesity-associated
intestinal tumorigenesis, we evaluated the development of tumor in the APC1638N mouse model
with or without VD or VD+SFN supplementation.

The dietary phytochemical SFN is an isothiocyanate found in cruciferous vegetables and has a
particularly high concentration in broccoli. SFN is known for its antitumor properties, but, the
mechanisms by which SFN might exert anticarcinogenic effects remain unclear. SFN inhibits
HDAC activity in many cancer cells(Dashwood and Ho 2008; Ho, Clarke et al. 2009; Dickinson,
Rusche et al. 2015; Kim, Fujita et al. 2016). Histone deacetylase inhibitors (HDACis) can alter
nuclear and cytoplasmic protein acetylation modify gene expression. Previous studies have
shown that HDACis alone or in combination with other anti-cancer agents are promising
treatment stragegies(Thurn, Thomas et al. 2011; Arrighetti, Corno et al. 2015; Ray, Das et al.
2018). Since activity of VD receptor (VDR) can be modulated epigenetically by histone
acetylation, the combination of VD and HDACi has been studied. Several studies have shown
that the combination of VD and HDACi is synergistic in cancer models, especially including
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those are resistant to VD alone(Rashid, Moore et al. 2001; Banwell, O'Neill et al. 2004; Khanim,
Gommersall et al. 2004; Malinen, Saramaki et al. 2008). However, there are little evidence on
the antitumor effect of combination of VD and SFN.

Chronic inflammation is a well-known risk factor for tumorigenesis. Previous studies have shown
that high fat diet can induce inflammation, in addition, VD and SFN might have anti-inflammation
property (Kim, Kim et al. 2014; Mousa, Misso et al. 2016). Therefore, we hypothesize that VD
and SFN supplementation can inhibit high fat diet induced inflammation.

It is well known that aberrant Wnt signaling play an important role in CRCs oncogenesis. We will
analyze the effects of VD and SFN on key signaling proteins of Wnt pathway by immunoblotting
analysis. We will measure the levels of phospho-GSK3β (Ser9), the inactive form of GSK3β,
and the dephosphorylated β-catenin (Ser37 or Thr41), the active form, which are two key
molecules in the Wnt pathway. We hypothesis that VD and SFN alleviates obesity induced
colon cancer through TNF-α/GSK3β/β-catenin pathway.

3.1.5 Aim 3
Butyrate is an intestinal microbiota metabolite of dietary fiber. It can exhibit chemoprevention
effects on CRCs development. However, the mechanistic action of butyrate remains to be
determined. FFAR2 has been suggested to mitigate colonic inflammation, which plays a pivotal
role in the development of colon cancer.
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The current study will assess whether FFAR2 protects against colon carcinogenesis. To
determine the effect of FFAR2, we will treat caco-2 cells with physiological concentrations of
butyrate (1, 2, 5 µM). To further measure the effects of FFAR2, we will perform siRNA to
knockdown the expression of FFAR2. To assess the activation of Wnt pathway and its
downstream genes, we performed Real time PCR and Western blot assay.
Immunohistochemical analysis was used to further confirm the activation of Wnt pathway.

3.1.6 Hypothesis 3
The assumption is that treatment of Caco-2 cells with butyrate, a HDAC inhibitor, will exert
antitumor effects. Caco-2 cells were cultured with the indicated concentration of butyrate for 24
h. The cell viability was determined by MTT assay and the cell apoptosis was assessed by flow
cytometry and expression of cleaved caspase-3.

Based on our preliminary data, we have shown that butyrate treatment increases the protein
expression of β-catenin. Therefore, it is possible that the antitumor effects of the butyrate are
mediated by a direct effect of butyrate on Wnt signaling. To test this hypothesis, we will examine
the activation of Wnt pathway and the expression of Wnt pathway downstream genes by the
Real time PCR and Western blot assay and immunohistochemical analysis.

It is not known the role of FFAR2 in the antitumor effects of butyrate. FFAR2 has been
suggested to regulate colonic inflammation, which is a major risk factor in colon carcinogenesis.
Previous studies have shown that the expression of FFAR2 have significantly reduced in
CRC(Tang, Chen et al. 2011; Bindels, Dewulf et al. 2013). Aberrant HDAC activity has been
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implicated in CRC progression. Therefore, we hypothesize that Knowdown of FFAR2 might
suppress the anticancer effects of butyrate. We will test our hypothesis by knowdown FFAR2
using siRNA then start the treatment of colon cancer cells with butyrate.
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CHAPTER 4
TUMOR NECROSIS FACTOR-Α KNOCK OUT MITIGATES INTESTINAL INFLAMMATION
AND TUMORIGENESIS IN APC1638N MICE FED A HIGH-FAT DIET

4.1 Abstract
Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world.
Previous study has shown diet-induced obesity is associated with elevated TNF-α and
hyperactive of Wnt signaling pathway, yet the role of TNF-α has not been extensively studied in
the obesity associated CRC. The present study aims to examine the role of TNF-α in the obesity
associated CRC and the molecular mechanism by which obesity increases the risk of CRCs.
Apc1638N mice were given a low fat diet (LF, 10 kcal% fat), or a high fat diet (HF, 60 kcal% fat).
TNF-a-/- Apc1638N mice were given a high fat diet (HF, 60 kcal% fat). After 16 weeks on diet
starting at 4-6 weeks of age, mice were euthanized with CO2. TNF-α deletion decreased CRC
incidence and size. Inflammation was suppressed by TNF-α deletion. TNF-α deletion also
decreased the activity of Wnt/b-catenin and NF-kB pathway. In this study, we found that loss of
TNF-α decreased obesity associated intestinal tumorigenesis by decreasing the inflammation,
and manipulating the β-catenin pathway and NF-kB signaling. In addition, IKK, component of
the NF-kB signaling, is involved in the regulation of β-catenin pathway.
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4.2 Introduction

Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is
the third most common cancer in the United States, with around 140,000 new cases being
diagnosed last year. The pathogenetic mechanisms underlying CRC development are complex
and include genetic and environmental factors. Wnt/β-catenin pathway is crucial in maintaining
colon homeostasis and colon stem cells. It is estimated that aberrant activation of the Wnt/βcatenin pathway is present in over 94% of human CRCs(2012). Most of them harbor mutations
in the adenomatous polyposis coli (APC) gene, which may result in the accumulation of βcatenin in the cytoplasm and subsequent translocation of β-catenin to the nucleus. In the
nucleus, β-catenin binds with the TCF/LEF family members and initiates the transcription of its
downstream genes.

There is strong evidence that modifiable lifestyle factors, including obesity, play a crucial role in
CRC carcinogenesis (Gunter and Leitzmann 2006). Since the prevalence of obesity is nearly
40% in the US adults, the study of obesity associated CRC becomes a top priority. Although
considerable efforts have been made, the mechanisms underlying the association between
obesity and CRC remain elusive. It is believed that obesity associated inflammation plays a
pivotal role in the CRC pathogenesis (Kolb, Sutterwala et al. 2016).

Tumor necrosis factor-α (TNF-α) is a potent pro-inflammatory cytokine which plays a key role in
the immune function during inflammation. TNF-α is mainly secreted by activated immune cells,
especially macrophages, mast cells, and T lymphocyte, but other cell types including cancer
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cells also secret TNF-α. TNF-α was first reported that it can induce tumor necrosis (Carswell,
Old et al. 1975). Interestingly, subsequent studies suggested that TNF-α might be a potential
cancer target, as it can induce cancer proliferation, migration, and angiogenesis. TNF-α induced
obesity might activate Wnt signaling, which drives the development of CRCs (Liu, Brooks et al.
2012). However, the understanding of molecular mechanisms by which obesity increases the
risk of CRCs is not complete.

As the prevalence of obesity increases alarmingly, it is urgent to find the safe and effective
strategies to prevent obesity associated CRC. In this study, we found that loss of TNF-α
decreased obesity associated intestinal tumorigenesis by decreasing the inflammation, and
manipulating the β-catenin pathway and NF-kB signaling. In addition, IKK, component of the
NF-kB signaling, is involved in the regulation of β-catenin pathway.

4.3 Materials and Methods
4.3.1 Animals
All animal study protocols were approved by the Institutional Animal Care and Use Committee
of the University of Massachusetts, Amherst, and animal experiments were conducted in
compliance with NIH guidelines for the care and use of laboratory animals. Apc1638N mice were
used as previously described (Li, Frederick et al. 2018). TNF-a knockout (TNF-a-/-) mice were
purchased from the Jackson Laboratory (Bar Harbor, ME). To produce TNF-a-/- Apc1638N mice,
TNF-a-/- mice were mated with Apc1638N mice on a C57BL/6 background.
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Apc1638N mice were given a low fat diet (LFD, 10 kcal% fat), or a high fat diet (HFD, 60 kcal%
fat) (APPENDIX A). TNF-a-/- Apc1638N mice were given a high fat diet (TNF-a KO HFD, 60 kcal%
fat). Fresh diet were given on a daily basis during the 16 weeks treatment. After 16 weeks on
diet starting at 4-6 weeks of age, mice were euthanized with CO2. Plasma samples were
collected and stored at -80 °C for analyses of cytokines. Tissue samples were collected using
the methods reported before (Liu, Brooks et al. 2012). Briefly, intestine was excised and opened
longitudinally for tumor inspection, then flushed with iced phosphate buffered saline (PBS)
containing a protease inhibitor cocktail and placed on a bed of crushed ice. The mucosa was
gently scraped off, placed in a foil packet, frozen in -80 °C and subsequently used for all DNA,
RNA and protein assays.

4.3.2 Inflammatory cytokine assays
The inflammatory cytokines were measured by a chemiluminescence assay using the
QuickPlex SQ 120 (Meso Scale Diagonostics, Rockville, MD). Assays were performed
according to the manufacturer’s instructions. Briefly, on the bottom of 96-well plates, antibodies
for 10 cytokines, TNF-α, IFN-γ, IL-1β, IL-17A, IL-6, IL-2, IL-10, IL-4, IL-22, and IL-23, were
coated, and then 25 µl of calibrator standards or samples were added to each well. After
washing for 3 times, 50 µl of the detection antibody solution was added to each well. A fourparameter logistic fit curve was generated for each analyte using the standards and the levels of
inflammatory cytokines in samples were calculated accordingly. Cytokines are express as ng of
cytokine per milliliter. All standards and samples were measured in duplicate.

4.3.3 Real-time PCR for gene expression
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RNA samples were extracted from the colonic scrapings with Trizol reagent (Invitorgen,
Carlsbad, CA). The concentration as well as purity of RNA samples was measured using
NanoDrop 2000 (Thermo Scientific, Waltham, MA). The first-strand cDNAs were synthesized
from total RNAs using QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). Real-time
PCR was performed on the ViiATM 7 Real-Time PCR System (Applied Biosystems, Carlsbad,
CA) using the SYBR green PCR reagent kit (Invitrogen, Carlsbad, CA). The copy number of
each transcript was calculated with respect to the GAPDH copy number. Primer sequences and
thermal cycling conditions were listed in APPENDIX B.

4.3.4 Western blot analyses
As reported before (Sun, Yu et al. 2011), 40 μg of protein from each treatment was separated
by 10% SDS-PAGE and transferred onto a PVDF membrane. After blocking with 10% instant
nonfat dry milk, membranes were incubated with specific antibodies overnight at 4 °C, followed
by incubation with the secondary antibody. Antibody binding was detected with the enhanced
ECL detection system. Notable western blots results were quantified using Image J software
after normalizing to corresponding loading controls.

4.3.5 Histopathological and immunohistochemical analysis
A section of colon, 3-5 μm, were fixed in 10% neutral buffered formalin, then processed for
paraffin embedding and tissue sectioning. Slides were stained with hematoxylin and eosin
(H&E) and observed under a light microscope to assess inflammation status of the colon. The
histological scores were evaluated by a blinded observer and given scores according to the
following measures: crypt architecture (scored 0-2 with 0 as normal and 2 as most crypt
distortion); inflammatory cell infiltration (0-2 with 0 as normal and 2 as most dense inflammatory
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infiltrate); goblet cell depletion (0-1 with 0 as goblet cells present and 1 goblet cell depleted) and
cryptitis (0-1 with 0 as absent and 1 present). The histological score is the sum of each score.
Immunohistochemical (IHC) analysis for specific proteins was performed as previously
described (Liu, Brooks et al. 2012). Briefly, after the sequential processes of rehydration and
antigen retrieval, tissue sections were incubated with primary antibodies overnight at 4°C, LC3B
(Cell Signaling), and Active β-Catenin (Ser33/37/Thr41) (Cell Signaling). On the next day, the
sections were incubated with peroxidase-labeled secondary antibody and developed using DAB
(Dako, Stanta Clara, CA). Positive signal was detected as a brown color under a light
microscope and scored using Fiji software. Briefly, run image and color deconvolution. Chose
“H DAB” as the stain. The intensity numbers of the “Color_2 image” in the results window were
converted to optical density numbers and then scored relative to control.

4.3.6 Statistical analysis
Values in the text are presented as means ± S.E.M. A one-way ANOVA (treatment) statistical
analyses were performed using Graphpad Prism 5 followed by multiple comparisons (Tukey
method) among all treatments (groups). To explicitly present the data in the figure, the
comparisons were only shown between the HFD group and other treatment groups. Values of p
< 0.05 were considered statistically significant among the comparisons. Fisher’s exact test was
used for tumor incidence. The expression of each gene was normalized to the housekeeping
gene GAPDH (DCt = Cttarget gene-CtGAPDH). Statistical analyses were performed based on ΔCt and
relative expression is reported as 2−ΔΔCt, where ΔΔCt=DCt-Experiment-DCt-Control.
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4.4. Results

4.4.1 TNF-α deficient mice less susceptible to obesity associated tumorigenesis
Previous study has shown diet-induced obesity is associated with elevated TNF-α and
hyperactive of Wnt signaling pathway, yet the role of TNF-α has not been extensively studied in
the obesity associated CRC (Liu, Brooks et al. 2012). To determine TNF-α function in obesity
associated CRC, we subjected animals from both genotypes to high fat diet. As expected, the
high fat diet induced obesity mice had increased incidence of CRC (HFD, 84.6%), compared
with mice fed a low fat diet (LFD, 46.2%). Loss of TNF-α decreased the incidence to 52.4%
(TNF-α KO HFD) (Figure 4.1A). For the tumor size, as measured by the diameter of the tumor,
the high fat diet-induced obesity significantly increased the tumor size (LFD: 0.18 cm ± 0.03 vs
HFD: 0.35 cm ± 0.04), loss of TNF-α decreased the tumor size by 35.4% (TNF-α KO HFD: 0.23
cm ± 0.03) (Figure 4.1B,C). These results indicate that TNF-α knockout can decrease obesity
associated CRC promotion and slow CRC progression.
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Figure 4.1. TNF-α knockout mice show less obesity associated carcinogenesis. A) Incidence of
obesity associated colon cancer. B) Average tumor size. C) Representative intestinal tumors of
each group. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01.

4.4.2 TNF-α knockout suppressed obesity associated inflammatory response
Chronic inflammation plays a pivotal role in obesity associated CRC. Obesity is recently
recognized as a chronic inflammation disease. In addition, TNF-α plays a key role in systemic
inflammation. We therefore determined the role of TNF-α in obesity associated inflammation. As
expected, high fat diet induced obesity is associated with an increased expression of TNF-α, IL1β, IL-6, and IFN-γ in peripheral plasma. TNF-α deletion led to a decreased expression of those
pro-inflammatory cytokines (Figure 4.2A-D). Considering the chronic local inflammation
mediated by TNF-α plays a pivotal role in tumor promotion, we then measured the local
inflammation status by histochemical staining. Consistently, our histochemical staining further
demonstrated that high fat diet induced obesity showed an increased inflammatory cell
infiltration, goblet cell loss, and cryptitis when compared to the low fat group (p < 0.01), TNF-α
deletion mitigated the intestinal mucosal damage (Figure 4.2E-F). These observations indicated
that TNF-α knockout suppressed obesity associated inflammatory response, which may involve
in the CRC prevention effect of TNF-α knockout.
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Figure 4.2. TNF-α deletion inhibits obesity associated inflammation. A-D) Analysis of
inflammatory cytokines in serum. Inflammatory cytokines were analyzed by chemiluminescent
assay (n = 8). E-F) Representative histopathology and inflammatory scores of the colon in each
group (n = 4-6). Inflammatory cell infiltration, goblet cell loss, and cryptitis were observed in
colon after feeding high-fat diet. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01.

4.4.3 TNF-α deletion down regulated active β-catenin and its downstream genes in
APC1638N mice
It is well known that aberrant Wnt signaling plays a crucial role in colorectal oncogenesis. We
therefore examined the effects of TNF-α deletion on Wnt signaling in CRC. By immunoblotting
analysis, we measured the levels of phospho-GSK3β (Ser9) protein, the inactive form of
GSK3β, and the dephosphorylated β-catenin (Ser37 or Thr41) protein, the active form, which
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are the two key molecules in the Wnt pathway. As shown in Figure 4.3A,B, high fat diet induced
obesity mice had increased expression of phospho-GSK3β (Ser9) and active β-catenin,
whereas, TNF-α knockout decrease the expression of phospho-GSK3β (Ser9) and active βcatenin. We further examined the mRNA expression of Wnt pathway downstream oncogenes,
Axin 2, c-Jun, c-Myc, and cyclin D1. Consistent with protein data, we found that the high fat diet
induced obesity mice had increased mRNA expression of these downstream genes, while TNFα knockout deceased the mRNA expression of these downstream genes (Figure 4.3C). To
further confirm these results, we performed immunohistochemistry. Immunohistochemistry also
revealed less β-catenin positivity in the TNF-α knockout group compared to the HFD group
(Figure 4.3D,E). Collectively, these results suggested that decreased activity of Wnt pathway
might be responsible for the cancer prevention effect of TNF-α knockout.
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Figure 4.3 TNF-α loss affects the expression of Wnt signaling. A-B) Representative western
blots and relative quantification of GSK-3βSer9 phosphorylation and active β-catenin in colonic
scrapings (n = 6-8). C) mRNA expression of Wnt pathway downstream genes (n = 5-8). D-E)
Representative β-catenin IHC in tissues from the small intestine of APC1638N mice (n= 4-6) and
quantification of immunohistochemical images. Data are presented as the mean ± SEM. *p <
0.05, **p < 0.01.

4.4.4 TNF-α deletion down regulated NF-kappa B signaling in APC1638N mice
NF-κB plays a key role in the regulation of inflammatory responses and carcinogenesis. TNF-α
can activate survival pathways which is mediated by the NF-κB (Gupta, Bi et al. 2005). We
therefore, examined whether TNF-α deletion can down regulate the NF-κB pathway. In NF-κB
pathway, cytokines such as TNF-a, IL-1 phosphorylate specific serine residues of nuclear factor
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NF-κB inhibitor kinase (IKKa and IKKb), which can then phosphorylate nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor (I-kB) and NF-kB p65, leading to the
activation of NF-κB pathway. Consistent with previous findings (Carlsen, Haugen et al. 2009;
Vykhovanets, Shankar et al. 2011), we observed that high fat diet induced obesity activated NFkappa B signaling in APC1638N mice (Figure 4.4A, B). TNF-a deletion decreased the expression
of p-IKKa(Ser176)/IKKb(Ser177), p-IkBa(Ser32), and p-NF-kB p65(Ser536), indicating the
down-regulation of NF-kB pathway.

Figure 4.4 TNF-α loss down regulates NF-kB pathway. A-B) Representative western blots and
relative quantification of p-IKKa(Ser176)/IKKb(Ser177), p-IkBa(Ser32), and p-NF-kB
p65(Ser536) in colonic scrapings (n = 6-8). Data are presented as the mean ± SEM. *p < 0.05,
**p < 0.01.
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4.4.5 IKK is involved in the obesity associated activation of β-catenin pathway
Previous studies suggested that IKK can activate Wnt/β-catenin pathway (Lamberti, Lin et al.
2001; Carayol and Wang 2006). We therefore, examined whether IKK is involved in the obesity
associated activation of β-catenin pathway. The effects of PS-1145, a potent IKK inhibitor, on
NF-kB pathway and β-catenin pathway were measured by western blot. Consistent with in vivo
data, TNF-α (20ng/ml) also activated NF-kB pathway and β-catenin pathway in Caco-2 cells.
The inhibition of IKK by PS-1145 reduced the activation of NF-kB pathway and β-catenin
pathway induced by TNF-α (Figure 4.5A). These data suggested that IKK is involved in the
obesity associated activation of β-catenin pathway.

Figure 4.5. NF-kB pathway positively regulated β-catenin pathway by IKK. A) Representative
western blots p-IkBa(Ser32), p-NF-kB p65(Ser536), p-GSK3b(Ser9), and active b-catenin in
caco-2 cell lines. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01.
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4.5 Discussion
Obesity, an epidemic, is a worldwide public health issues especially in developed countries.
Obesity is associated with increased risk of many chronic diseases, such as cancer, diabetes,
and chronic heart diseases. It is estimated that obesity attributes a 30% greater risk of CRC(Ma,
Yang et al. 2013). In the United States, ~1/3 of the population is obese and there is no sign of
decrease from the current prevalence of obesity. CRC is the third leading cause of cancer death
in the United States in both men and women. In 2018, it is estimated that ≈ 64 640 women and
75 610 men in the United States were diagnosed with CRC and 23 240 women and 27 390 men
died from CRC. Therefore, it is urgent to develop safe and practical strategies to prevent obesity
associated CRC.

It is believed that obesity associated inflammation is a central component of CRC development
and progression. Among inflammatory cytokines, TNF-α plays a crucial role in obesity
associated inflammation (Liu, Brooks et al. 2012). TNF-α was first found in 1975, recognized as
a promising strategy for cancer treatment. However, previous studies have shown that TNF-α
can be secreted by many tumor cells (Zins, Abraham et al. 2007; Al-Lamki, Sadler et al. 2010;
Aggarwal, Gupta et al. 2012; Landskron, De la Fuente et al. 2014). As a result, the role of TNFα in tumor survival, migration, and invasion, are more and more appreciated. In 1993, a study
first suggested that TNF-α might implicate in the oncogene activation and the DNA damage (Li,
Sejas et al. 2007). Subsequent clinic trails indicated that neutralizing TNF-α might be beneficial
in cancer patients (Brown, Charles et al. 2008).

Popivanova et al have suggested that TNF-α plays a crucial role in the initiation of ulcerative
colitis (UC) associated colon cancer (Popivanova, Kitamura et al. 2008). Blocking TNF-α can
54

decrease the CRC progression in mice UC model treated with azoxymethane (AOM) and
dextran sulfate sodium (DSS). Liu et al reported that high fat diet induced obesity is associated
with a 72% increase in the expression of TNF-α and increased expression of p-GSK3β, βcatenin, and Wnt downstream genes. Previous studies have shown that TNF-α can induce
GSK3β phosphorylation and subsequently stabilize β-catenin (Oguma, Oshima et al. 2008; Liu,
Brooks et al. 2012; Coskun, Olsen et al. 2014), two key components within Wnt pathway.
Considering the fact that Wnt signaling is crucial for CRC incidence and progression, TNF-α
deletion might decrease the Wnt signaling and incidence of CRC. In this study, we found that
TNF-α knockout decrease the incidence of CRC from 84.6% to 52.4% and tumor size by 35.4%
in Apc1638N mice fed a high fat diet. Our observation indicated that blocking TNF-α might be a
strategy to prevent obesity associated CRC. We also found that TNF-α knockout decreased
obesity associated inflammation. Previous studies have suggested that TNF-a might activate
Wnt/β-catenin pathway through inducing GSK3β phosphorylation (Oguma, Oshima et al. 2008;
Liu, Brooks et al. 2012; Coskun, Olsen et al. 2014). In consistent with these studies, we found
that TNF-α deletion decreased the expression of phospho-GSK3β (Ser9) and active β-catenin,
indicating the cancer prevention effects of TNF-α deletion might act through down-regulation of
Wnt/β-catenin pathway.

NF-κB is involved in the regulation of inflammatory responses and cancer development,
therefore, NF-κB plays a pivotal role in the obesity associated CRC. IKKa and IKKb are
essential for TNF-a induced NF-kB activation (Tak and Firestein 2001). Phosphorylated IKKa
and IKKb can then phoshporylate I-kB and NF-kB p65, leading to NF-kB translocation to the
nucleus. Consistent with previous findings (Carlsen, Haugen et al. 2009; Vykhovanets, Shankar
et al. 2011), we observed that high fat diet induced obesity activated NF-kB signaling and TNFa deletion down regulated of NF-kB pathway in APC1638N mice. There is crosstalk between
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Wnt/β-catenin pathway and NF-kB pathway during inflammation, for instance, IKK can activate
Wnt/β-catenin pathway (Lamberti, Lin et al. 2001; Carayol and Wang 2006). Our data indicated
that NF-kB signaling might positively regulate the Wnt/β-catenin pathway through IKK, which
can activate IkBa and NF-kB, at the same time activate GSK3β and β-catenin.

4.6 Conclusions
In conclusion, we found that TNF-α deletion decreased obesity associated intestinal
tumorigenesis by decreasing the production of multiple proinflammatory cytokines, and
downregulated the β-catenin pathway and NF-kB signaling. IKK, component of the NF-kB
signaling is involved in the regulation of β-catenin pathway.
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CHAPTER 5
THE PREVENTION OF A HIGH DOSE OF VITAMIN D OR ITS COMBINATION WITH
SULFORAPHANE ON INTESTINAL INFLAMMATION AND TUMORIGENESIS IN APC1638N
MICE FED A HIGH-FAT DIET

5.1 Abstract
Our previous study showed that obesity-promoted inflammation is responsible for the activation
of the intestinal tumorigenic Wnt-signaling. The present study aimed to test a dietary strategy,
dietary supplementation with a high dose of vitamin D (VD) or its combination with sulforaphane
(SFN), to inhibit intestinal inflammation and obesity-associated tumorigenesis. Apc1638N mice
were randomly divided into 4 groups: LF, a low fat diet (10 kcal% fat) with 200 IU VD; HF, a high
fat diet (60 kcal% fat) with 200 IU VD; HFD: a high fat diet with 5,000 IU VD; and HFDS, a high
fat diet plus 5,000 IU VD and 0.23 g SFN per ~4,000 kcal. VD administration decreased tumor
incidence and size, and the co-administration with SFN (HFDS) magnified the effects.
Inflammation and Wnt-signaling were suppressed by VD. The addition of SFN decreased the
activity of histone deacetylase (HDAC) and increased autophagy. The administration of VD, at
5000 IU level, exerts an anti-inflammatory property, and leads to suppressed intestinal Wntsignaling and tumorigenesis in obese mice. The molecular function of SFN on a high dose of VD
supplementation, although displayed on the inhibition of HDAC and the activation of autophagy,
needs further investigation.
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5.2 Introduction
Colorectal cancer (CRC) is the third leading cause of cancer death in the United States. In
2018, it is estimated that ~64,640 women and 75,610 men in the United States were diagnosed
with CRC and 23,240 women and 27,390 men died from CRC. Epidemiological studies have
shown that a number of modifiable lifestyle factors, including obesity, play important roles in
colorectal carcinogenesis (Gunter and Leitzmann 2006). There is strong evidence suggesting
that chronic overconsumption of a “western diet”- foods consisting high levels of fats is a major
cause of obesity. In the United States, ~1/3 of the population is obese and there is no sign of
decrease from the current prevalence of obesity. Therefore, developing a safe and economic
strategy to prevent obesity-induced CRC is an important public health priority.

Vitamin D (VD), is a pluripotent fat-soluble steroid that is essential for a variety of physiological
and pathological processes in the human body. In addition to its important role in calcium
absorption and bone health (Rautiainen, Manson et al. 2016; Uday and Hogler 2017), VD
regulates a number of critical cellular pathways that affect cell proliferation, differentiation, and
apoptosis. Therefore, VD potentially plays an important role in modulating cancer incidence,
prognosis, and mortality (Fleet 2008; Ng 2014). However, epidemiological and clinical VD
supplementation studies have shown inconsistent results. For example, in a sub-study of the
Women’s Health Initiative trail, dietary supplementation with 400 IU of VD did not significantly
reduce the risk of CRC (Brunner, Wactawski-Wende et al. 2011), however, it should be noticed
that the supplement of 400 IU of VD per day did not significantly elevate the serum 25(OH)D
level, a biomarker of VD status. In another study, dietary supplementation with 2,000 IU of VD
did not lower the risk of CRC (Lappe, Watson et al. 2017); However, in a phase II clinical trial, a
high dose of VD (8,000 IU for two weeks, followed by 4,000 IU) suppressed the progression of
colon cancer (Ng, Nimeiri et al. 2017). Therefore, in this study, we examined the protective
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effect of a high dose of VD (5,000 IU per ~4,000 kcal), on the development of intestinal tumor in
the Apc1638N model.

In addition, we further examined whether sulforaphane (SFN), an isothiocyanate derived from
cruciferous vegetables, can magnify the anti-cancer effects of VD supplementation.
Epidemiologic studies suggest that higher intake of cruciferous vegetables is associated with
lower risk of CRC (Wu, Yang et al. 2013). Mechanisms of cancer chemoprevention by SFN
include the ability to induce apoptosis of cancer cells by a mitogen-activated protein kinase
(MAPK) pathway and the ability to alter carcinogen metabolism through the induction of Nrf2regulated genes. It has also been suggested that SFN inhibits histone deacetylase (HDAC)
activity in human CRC cell lines (Ho, Clarke et al. 2009), and VD may interact with SFN to affect
on gene expression through epigenetic mechanisms (e.g., chromatin acetylation) (Zhang, Leung
et al. 2012; Seuter, Heikkinen et al. 2013). Of note, HDAC activity was significantly inhibited in
the peripheral blood mononuclear cells after consumption of 68 g (∼105 mg SFN) of broccoli
sprouts (Myzak, Tong et al. 2007). Therefore, SFN, even at physiologically feasible
concentrations, might enhance the anti-cancer effect of VD.

5.3 Materials and Methods
5.3.1 Animals
The protocol (2013-0070) was approved by the Institutional Animal Care and Use Committee of
the University of Massachusetts Amherst, and animals were maintained in accordance with NIH
guidelines for the care and use of laboratory animals. Apc1638N mice, which are heterozygous for
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a germline mutation in the Apc gene, were utilized to study intestinal tumorigenesis. Compared
to another commonly-used CRC model, the ApcMin mice, the Apc1638N mice have a mild
tumorigenic phenotype (3 vs 100 tumors) and longer lifespan (>1 years vs 4-6 months) (Heyer,
Yang et al. 1999; Taketo 2006), making it a more suitable models for dietary intervention studies
since the modest degree of chemoprevention afforded by nutrients can easily be obscured in
animals with more aggressive tumorigenic phenotypes. Although most genetic models, including
the Apc1638N model, produce neoplasms primarily in the small intestine rather than the colon, this
does not negate their validity since mouse models with Apc mutations share the same genetic
and phenotypic similarities to humans with familial adenomatous polyposis, and moreover, the
mouse and human APC orthologs are approximately 90 % identical (Shoemaker, Gould et al.
1997). In many instances the modulation of small intestinal tumors recapitulates the
chemopreventive effects of drugs and dietary components in human colon cancer (Yang,
Edelmann et al. 1998).

Apc1638N mice, including both males and females, were randomly divided into 4 dietary groups,
~12 animals/group: LF, a low fat diet (10 kcal% fat) with 200 IU VD; HF, a high fat diet (60
kcal% fat) with 200 IU VD; HFD: a high fat diet with 5,000 IU VD; and HFDS, a high fat diet plus
5,000 IU VD and 0.23 g SFN on a 4,057kcal energy basis (APPENDIX A). Because a previous
human study suggested that 68 g broccoli sprouts (∼105 mg SFN) significantly inhibited HDAC
activity (Myzak, Tong et al. 2007) and a typical diet contains 2,000kcal, we therefore added 0.23
g SFN on a 4,057kcal energy basis to achieve a physiologically relevant concentration. Fresh
diet was given on a daily basis during the 16 weeks of dietary treatment. The 5000 IU VD,
although 5 times higher than the National Research Council requirement for mice (1000 IU), is
physiologically achievable without evident toxicity (Fleet, Gliniak et al. 2008). Since this study
focused on evaluating the effect of a high dose of VD, and whether SFN can magnify this effect,
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we did not include a group with SFN supplementation alone to demonstrate their synergistic
effects. After 16 weeks on a diet starting at 4-6 weeks of age, mice were euthanized with CO2.
Plasma samples were collected and stored at -80 °C for analyses of cytokines. Tissue samples
were collected using the methods reported before (Liu, Brooks et al. 2012). Briefly, intestine was
excised and opened longitudinally for tumor inspection, then flushed with iced phosphate
buffered saline (PBS) containing a protease inhibitor cocktail and placed on a bed of crushed
ice. The mucosa was gently scraped off, placed in a foil packet, frozen in -80 °C and
subsequently used for all DNA, RNA and protein assays.

5.3.2 Serum 25(OH)D Assay
Serum 25-hyroxyvitamin D (25(OH)D) was measured by radioimmunoassay using LIAISON
total 25(OH)D assay (DiaSorin Inc., Stillwater, MN, USA) at the Jean Mayer USDA Human
Nutrition Research Center on Aging at Tufts University. This method has been previously
validated and reported (Selting, Sharp et al. 2016).

5.3.3 Inflammatory cytokine assays
The inflammatory cytokines were measured by an chemiluminescence assay using the
QuickPlex SQ 120 (Meso Scale Diagonostics, Rockville, MD). Assays were performed
according to the manufacturer’s instructions. Briefly, on the bottom of 96-well plates, antibodies
for 10 cytokines, TNF-α, IFN-γ, IL-1β, IL-17A, IL-6, IL-2, IL-10, IL-4, IL-22, and IL-23, were
coated, and then 25 µl of calibrator standards or samples were added to each well. After
washing for 3 times, 50 µl of the detection antibody solution was added to each well. A fourparameter logistic fit curve was generated for each analyte using the standards and the levels of

61

inflammatory cytokines in samples were calculated accordingly. Cytokines are express as ng of
cytokine per milliliter serum. All standards and samples were measured in duplicate.

5.3.4 Real-time PCR for gene expression
RNA samples were extracted from the colonic scrapings with Trizol reagent (Invitorgen,
Carlsbad, CA). The concentration as well as purity of RNA samples was measured using
NanoDrop 2000 (Thermo Scientific, Waltham, MA). The first-strand cDNAs were synthesized
from total RNAs using QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). Real-time
PCR was performed on the ViiATM 7 Real-Time PCR System (Applied Biosystems, Carlsbad,
CA) using the SYBR green PCR reagent kit (Invitrogen, Carlsbad, CA). The copy number of
each transcript was calculated with respect to the GAPDH copy number. Primer sequences and
thermal cycling conditions were listed as supporting information in APPENDIX B.

5.3.5 Western blot analyses
As reported before (Sun, Yu et al. 2011), 40 μg of protein from each treatment was separated
by 10% SDS-PAGE and transferred onto a PVDF membrane. After blocking with 10% instant
nonfat dry milk, membranes were incubated with specific antibodies overnight at 4°C, followed
by incubation with the secondary antibody. Antibody binding was detected with the enhanced
ECL detection system. Notable western blots results were quantified using Image J software
after normalizing to a corresponding loading controls.

5.3.6 Histopathological and immunohistochemical analysis
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A section of colon, 3-5 μm, were fixed in 10% neutral buffered formalin, then processed for
paraffin embedding and tissue sectioning. Slides were stained with hematoxylin and eosin
(H&E) and observed under a light microscope to assess inflammation status of the colon. The
histological scores were evaluated in a blinded manner and given scores according to the
following measures: crypt architecture (scored 0-2 with 0 as normal and 2 as most crypt
distortion); inflammatory cell infiltration (0-2 with 0 as normal and 2 as most dense inflammatory
infiltrate); goblet cell depletion (0-1 with 0 as goblet cells present and 1 goblet cell depleted) and
cryptitis (0-1 with 0 as absent and 1 present). The histological score is the sum of each score.
Immunohistochemical (IHC) analysis for specific proteins was performed as previously
described (Liu, Brooks et al. 2012). Briefly, after the sequential processes of rehydration and
antigen retrieval, tissue sections were incubated with primary antibodies overnight at 4°C for
LC3B (Cell Signaling), and active β-Catenin (Ser33/37/Thr41) (Cell Signaling). On the next day,
the sections were incubated with peroxidase-labeled secondary antibody and developed using
DAB (Dako, Stanta Clara, CA). Positive signal was detected as a brown color under a light
microscope and scored using Fiji software. Briefly, images were uploaded to Fiji, and the color
was deconvoluted. Chose “H DAB” as the stain. The intensity numbers of the “Color_2 image” in
the results window were converted to optical density numbers and then scored relative to
control.

5.3.7 HDAC Activity Assay
Nuclear extracts, prepared as described by Dignam (Dignam, Lebovitz et al. 1983), were used
for HDAC activity assay using EpiQuik HDAC Activity/Inhibition Assay Kits (Epigentek,
Farmingdale, NY) according to the manufacturer’s instructions. Briefly, 10 μg of nuclear extract
was incubated with specific substrate for 45 min at 37 °C, followed by incubation with capture
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antibody for 60 min and then detection antibody for 25 min at room temperature. Absorbance
was determined at 450 nm using a microplate spectrophotometer.

5.3.8 Statistical analysis
Values in the text are presented as means ± S.E.M. One-way ANOVA (treatment) statistical
analyses were performed using Graphpad Prism 5 followed by multiple comparisons (Tukey
method) among all treatments (groups). To simplify data presentation in the figures, the
comparisons were only shown between the HF groups with other treatment groups. Values of p
< 0.05 were considered statistically significant among the comparisons. Fisher’s exact test was
used for tumor incidence. The expression of each gene was normalized to the housekeeping
gene GAPDH (DCt = Cttarget gene-CtGAPDH). Statistical analyses were performed based on ΔCt and
relative expression is reported as 2−ΔΔCt, where ΔΔCt=DCt-Experiment-DCt-Control.

5.4 Results
5.4.1 Influence on serum 25(OH)D and physiology by 5000 IU vitamin D supplementation
Previous studies indicate that a concentration of 60-80 ng/ml serum 25(OH)D, the major
circulating form of VD and a standard indicator of vitamin D status, may be needed to reduce
cancer risk (Garland, French et al. 2011). We therefore intentionally supplemented VD with a
concentration of 5000 IU for the supplemental groups vs 200 IU for the control groups, which is
lower than the NRC recommended level (1000 IU) for rodents on a ~4,000 kcal energy basis.
This level of vitamin D was chosen as a better mimic of human vitamin D status as described by
Fleet et al (Fleet, Gliniak et al. 2008) and Kallay et al (Hummel, Thiem et al. 2012). Serum levels
of 25(OH)D in LF and HF group are 23.4±5.6 ng/ml, 14.3±1.7 ng/ml respectively, and levels in
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the two VD supplemental groups (HFD and HFDS) were 62.0±2.3 ng/ml, 52.4±5.4 ng/ml
respectively, which were significantly higher than the levels in the LF and HF groups (p < 0.01)
(Figure 1A). With the consideration of potential toxicity by 5,000 IU VD supplementation, we
examined the physiological alterations. No significant differences were observed in liver,
pancreas, spleen, and kidney between in the VD supplemental groups (HFD and HFDS) when
compared to the control group (HF).

After 16 weeks treatment, the final body weights in LF, HF, HFD, and HFDS groups were 37.6 ±
1.4g, 45.7 ± 1.8g, 45.0 ± 1.9g, 43.0 ± 1.4g, respectively (Figure 5.1B, D). The final epididymal
fat weights in LF, HF, HFD, and HFDS mice were 1.8 ± 0.1g, 2.6 ± 0.2g, 2.5 ± 0.2g, 2.1 ± 0.3g,
respectively (Figure 5.1C). The final body weights and epididymal fat weights were significantly
higher in the HF group relative to the control LF group (p < 0.05), but the supplementation of VD
alone (HFD) or VD with SFN (HFDS) did not significantly decrease the body weight and
epididymal fat weight (p > 0.05).
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Figure 5.1. Influence on serum 25(OH)D and physiology by 5000IU kg−1 vitamin D
supplementation. A) Serum 25(OH)D levels among the four dietary groups. B) Growth curve:
Body weights were measured every other week. C) Epididymal adipose tissue weights in each
group. D) Appearance of mice at the end of diets feeding. *p < 0.05, **p < 0.01. Data are mean
± SEM.

5.4.2 A high degree of vitamin D supplementation and its co-administration with
sulforaphane inhibited obesity associated-intestinal tumorigenesis in APC1638N mice
To investigate the effect of VD or VD in combination with SFN in obesity-associated intestinal
tumorigenesis, we evaluated the development of tumor in the APC1638N mouse model with or
without VD or VD+SFN supplementation. The high fat diet increased the tumor incidence from
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46.1% (LF) to 84.6% (HF), whereas the supplementation of VD or VD in combination with SFN
decreased the incidence to 63.6% (HFD) and 53.8% (HFDS) (Figure 5.2A). For the tumor size,
as measured by the diameter of the tumor, the high fat diet significantly increased the size (LF:
0.18 cm ± 0.03 vs HF: 0.35 cm ± 0.04), whereas the administration of VD or its coadministration with SFN reduced the tumor size by 22.9% (0.27 cm ± 0.02) and 37.1% (0.22 cm
± 0.02) respectively (Figure 5.2B, C). These data indicated that the supplementation of VD or its
co-administration with SFN suppressed high fat diet-induced intestinal tumorigenesis in the
APC1638N model, although only the shrinking of tumors in the co-administration group (HFDS)
was reached a statistically significant degree (p < 0.05).
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Figure 5.2. The influence of a high dose of vitamin D or its combination with sulforaphane on
intestinal tumorigenesis in APC1638N mouse model. A) Incidence of high-fat-diet-induced colon
cancer. B) Average tumor size. C) Representative intestinal tumors of each group. Data are
presented as the mean ± SEM. *p < 0.05, **p < 0.01.

5.4.3 The influence vitamin D or its combination with sulforaphane supplementations
suppressed high fat diet-induced inflammatory response
Chronic inflammation is a well-known risk factor for tumorigenesis. Previous studies have shown
that high fat diet can induce inflammation, and VD and SFN might have anti-inflammatory
properties (Kim, Kim et al. 2014; Mousa, Misso et al. 2016). Therefore, we examined to what
extent VD and SFN supplementation can inhibit high fat diet-induced intestinal inflammation. We
observed that VD alone significantly reduced (p < 0.05) the high fat diet- induced production of
pro-inflammatory cytokines TNF-α, INF-γ, IL-2, and IL-17A, with a trend to decrease the
production of IL-1β, and a trend to increase the secretion of the anti-inflammatory cytokine IL-10
(Figure 5.3A). The combination of VD and SFN did not further augment the anti-inflammatory
effect of VD. We did not observed any significant changes in the production of IL-6, IL-4, IL-22,
and IL-23 cytokines by VD or its combination with SFN supplementations (data not shown). Our
histochemical staining further demonstrated that high fat diet increased the intestinal
inflammatory score when compared to the low fat group (p < 0.01), but VD (HFD) or VD and
SFN co-supplementation (HFDS) diminished inflammatory cell infiltration, goblet cell loss and
cryptitis induced by high fat diet, with a change that reached a significant degree in the HFDS
group (p < 0.05). There were no significant differences of between HFD and HFDS group
(Figure 5.3B, C).
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Figure 5.3. Effect of vitamin D and sulforaphane on inflammation. A) Analysis of inflammatory
cytokines in serum inflammatory cytokines were analyzed by chemiluminescent assay (n = 8).
B) Representative histopathology and inflammatory scores of the colon in each group (n = 6).
Inflammatory cell infiltration, goblet cell loss, and cryptitis were observed in colon after feeding
high-fat diet. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01.

5.4.4 The supplementation of vitamin D and sulforaphane down-regulated active bcatenin and its downstream targets in APC1638N mice
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We further studied the effects of VD and SFN supplementation on signaling pathways involved
in CRC. It is well known that aberrant Wnt signaling plays an important role in driving cell
proliferation during colorectal oncogenesis. By immunoblotting analysis, we measured the levels
of phospho-GSK3β (Ser9) protein, the inactive form of GSK3β, and the dephosphorylated βcatenin (Ser37 or Thr41) protein, the active form, which are two key molecules in the Wnt
pathway. As shown in Figure 5.4A, the expression of phospho-GSK3β (Ser9) and active βcatenin in the colon mucosa was increased in the HF group compared to the LF group,
whereas, VD significantly deceased expression of phospho-GSK3β and dephosphorylated βcatenin. Co-administration VD with SFN did not further decrease the expression of phosphoGSK3β and dephosphorylated β-catenin. Immunohistochemistry also revealed less β-catenin
positivity in HFD and HFDS groups compared to HF group (Figure 5.4B). We further examined
the mRNA expression of Wnt pathway downstream oncogenes, Axin 2, c-Jun, c-Myc, and cyclin
D1. We found that the mRNA expressions of these downstream genes were increased in HFDinduced obese mice, while VD alone led to decreased expressions of these genes (Figure
5.4C). However, combining VD with SFN did not further inhibit the expression of the Wnt
pathway downstream genes.

70

Figure 5.4. Effect of vitamin D and sulforaphane supplementation on β-catenin and its
downstream genes. A) Representative Western blots and relative quantification of GSK-3β Ser9
phosphorylation and active β-catenin in colonic scrapings (n = 6). B) Representative β-catenin
IHC in tissues from the small intestine of APC1638N mice (n = 5) and quantification of
immunohistochemical images. C) mRNA expression of Wnt pathway downstream genes (n = 8).
Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01.

5.4.5 The sulforaphane supplementation decreased the total HDAC activity.
To investigate whether the supplementation of SFN suppressed HDAC activities, the total
HDAC activities were measured in nuclear extracts of mucosa. The SFN treatment group
(HFDS) displayed significantly decreased level of total HDAC activities when compared to other
groups (p < 0.05), and there were no differences among other groups without SFN
supplementation (LF, HF, HFD) (Figure 5.5A). Western blotting results also showed that the
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SFN administration decreased the HDAC6 protein level (Figure 5.5B). This provides evidence
that the addition of SFN may be responsible for the enhanced antitumor effects by inhibition of
HDAC activity.

Figure 5.5. Effect of vitamin D and sulforaphane supplementation on the total histone
deacetylase (HDAC) activity and the expression of vitamin D receptor. A) The total HDAC
activity. B) Western blotting for HDAC6. Representative picture of Western blotting. Data are
presented as the mean ± SEM (n = 3–5). *p < 0.05.

5.4.6 The supplementation of vitamin D and sulforaphane enhanced autophagy in
APC1638N mice
Autophagy has been recognized as a basis for the health-promoting effects of VD (HoyerHansen, Nordbrandt et al. 2010). Previous studies also suggested that SFN induces autophagy
in human colon cancer (Nishikawa, Tsuno et al. 2010), prostate cancer(Herman-Antosiewicz,
Johnson et al. 2006), and breast cancer(Kanematsu, Uehara et al. 2010). To examine the role
of autophagy in the protective effects of VD and SFN, we analyzed the level of LC3-ll, a wellknown marker of autophagy. As shown in Figure 5.6A, the level of LC3-ll in mice treated with
VD was significantly increased (2.2 fold) when compared to mice in HF group (p < 0.05). The
addition of SFN further significantly increased the level of LC3-ll (3.8 fold) compared to mice in
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HF group (p < 0.01). To monitor autophagic flux, we further measured the level of P62, which
serves as a link between LC3 and ubiquitinated substrates and is efficiently degraded by
autophagy. After treatment with VD, P62 was markedly decreased, consistent with increased
autophagy activity. In addition, the addition of SFN further decreased the level of P62, indicating
autophagic activation. IHC results also show that, compared to mice in HF and HFD group, a
strong staining of LC3-II was detected in mice treated with the co-supplementation (Figure
5.6B). These results suggested that a high dose of VD supplementation can enhance the
activity of autophagy, and the addition of SFN can magnify this effect.

Figure 5.6. Effect of vitamin D and sulforaphane supplementation on the expression of LC3-ll, a
marker of autophagy. A) Representative Western blots and relative quantification of LC3-ll in
colonic scrapings (n = 6). B) Representative LC3-ll IHC in tissues from the small intestine of
APC1638N mice (n = 5) and quantification of immunohistochemical images. Data are presented
as the mean ± SEM. *p < 0.05, **p < 0.01.
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5.5 Discussion
Epidemiological studies have established obesity as a predisposing risk factors for CRC
(Renehan, Tyson et al. 2008). Obesity rates have been steadily rising, and the prevalence of
obesity among adults increased from 33.7% in 2007-2008 to 39.6% in 2015-2016 (Hales, Fryar
et al. 2018). If this trend continues, there is no chance that the world could meet the target set
by the UN as of 2025 (Di Cesare, Bentham et al. 2016). Therefore, it is necessary and urgent to
understand the mechanisms by which obesity raises the risk of CRC and to design efficient and
economic strategies to address this problem.

Substantial epidemiologic and experimental studies have shown that higher intake or blood
levels of VD is associated with the low risk of CRC (Wactawski-Wende, Kotchen et al. 2006;
Gorham, Garland et al. 2007; Jenab, Bueno-De-Mesquita et al. 2010; Lee, Li et al. 2011; Grant
2012), and a randomized, controlled clinical trial suggested that VD supplementation might
decrease tumor-promoting inflammatory biomarkers such as TNF-a, IL-6, IL-1β, IL-8 (Hopkins,
Owen et al. 2011). Since the initial discovery of escalated expression of TNF-α in adipose tissue
in1993 (Hotamisligil, Shargill et al. 1993), it is now well accepted that obesity is associated with
a state of chronic low-grade inflammation (Ramos, Xu et al. 2003), which is at least partially
responsible for obesity-associated CRC (Coussens and Werb 2002). Therefore, VD
supplementation holds promise as an effective dietary strategy for the prevention of obesityassociated CRC. However, VD clinical studies have unfortunately been disappointing
(Wactawski-Wende, Kotchen et al. 2006; Baron, Barry et al. 2015; Song, Garrett et al. 2015).
Major reasons that may explain the inconsistency in findings among these studies include the
dosage of supplementation (Wactawski-Wende, Kotchen et al. 2006; Baron, Barry et al. 2015;
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Song, Garrett et al. 2015) and the fact that nutrients in foods more likely act in concert with each
other and the assumption that a single nutrient alone has a substantial individual anti-cancer
effect may not be valid (Jacobs and Steffen 2003; Flood, Rastogi et al. 2008). One randomized
controlled trial (RCT) study found that daily supplementation of 400 IU VD with calcium had no
effect on the incidence of CRC among postmenopausal women (Wactawski-Wende, Kotchen et
al. 2006). One possible explanation for this observation was that 400 IU VD daily is too low of a
dose, considering the fact that the mean increment in 25(OH)D caused by an additional 1,000
IU/d is only 8 ng/ml at a starting value of 30 ng/ml(Garland, French et al. 2011). In another RCT
study, supplementation with a higher VD dose (2,000 IU/d) and calcium di d not result in a
significantly lower risk of all-type cancers at 4 years (Lappe, Watson et al. 2017). This might be
due to a relatively high mean baseline serum 25(OH)D levels (32.8 ng/ml) in these healthy
postmenopausal older women. In our study, the mean baseline serum 25(OH)D levels of HF
group was 14.3±1.7 ng/ml. In addition, another RCT study suggested that high doses of VD
(8,000 IU/d for two weeks, followed by 4,000 IU/d) suppressed the progression of colon cancer.
Therefore, in the present study, we investigated the preventive effect of a high dose VD (5000
IU) and its combination with SFN on intestinal inflammation and tumorigenesis in obese Apc1638N
mice. Serum levels of 25(OH)D in the high dose VD supplementation groups (HFD and HFDS)
were 62.0±2.3 ng/ml, 52.4±5.4 ng/ml respectively, which is consistent with a previous
study(Hummel, Thiem et al. 2013).

VD, via its most active metabolite 1,25-dihydroxyvitamin D3 [1,25(OH)2D], plays an important
role in cellular processes by binding the nuclear VD receptor transcription factor and affecting
expression of key genes involved in control of cellular proliferation, differentiation, and apoptosis
(Deeb, Trump et al. 2007). Possible mechanisms underlying Wnt/β-catenin inhibition by
1,25(OH)2D in colon cancer is that: 1,25(OH)2D inhibits the production of IL-1β in THP1
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macrophages, and thereby inhibits the ability of macrophages to activate Wnt signaling in colon
carcinoma cells (Kaler, Augenlicht et al. 2009). It has also been proposed that the
chemopreventive properties of 1,25(OH)2D stem from its ability to increase the binding of VDR
to β-catenin, thereby hampering the formation of the β-catenin/TCF complexes, and to induce
the expression of the Wnt inhibitor DKK1 (Aguilera, Pena et al. 2007). SFN, an isothiocyanate
found in cruciferous vegetables, has the property to inhibit HDAC activity in many cancer cells
(Dashwood and Ho 2008; Ho, Clarke et al. 2009; Dickinson, Rusche et al. 2015; Kim, Fujita et
al. 2016). Several studies have shown that the HDAC inhibitors (HDACi) can improve the effects
of VD supplementation and HDACi can cause a synergistic effect in cancer models, especially
those that are resistant to VD supplementation alone (Rashid, Moore et al. 2001; Banwell,
O'Neill et al. 2004; Khanim, Gommersall et al. 2004; Malinen, Saramaki et al. 2008). However,
there are little evidence about the antitumor effect of the combination of VD and SFN.

In the present study, we demonstrated that a high dose of VD supplementation can significantly
attenuated the obesity-induced elevated expression of TNF-a by 28.33%, IFN-γ by 39.24%, IL-2
by 66.49%, IL-17A by 54.94% by 60 kcal% high fat diet. Previous studies have shown that TNFa can induce GSK3β phosphorylation and subsequently stabilize β-catenin (Oguma, Oshima et
al. 2008; Liu, Brooks et al. 2012; Coskun, Olsen et al. 2014), two key components within Wnt
pathway. Our data showed that the high dose VD supplementation can decrease the level of
phospho-GSK3β and active β-catenin, in parallel with decreased mRNA expression of Axin 2, cJun, c-Myc, and Cyclin D1, which are reported as Wnt pathway downstream genes. These
obeservations are in agree with previous studies that have shown that 1,25(OH)2D can inhibit
Wnt-signaling and its downstream genes, such as c-Myc, cyclin D1 (Tong, Hofer et al. 1999;
Larriba, Ordonez-Moran et al. 2011).
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Our findings from this study demonstrated that co-administration of VD with SFN further
decreased tumor incidence (HFD: 63.6% vs HFDS: 53.8%) and tumor size (HFD: 0.27cm vs
HFDS: 0.22cm), but none of them reached a statistically significant degree. These observations,
in agreement with previous findings (Shen, Khor et al. 2007), indicate the combination of dietary
phytochemical SFN with other antitumor agents, such as VD, may be beneficial in CRC
prevention. The co-administration (HFDS group) failed to further decrease tumor-promoting
inflammatory cytokines and alter components of the Wnt pathway. Nevertheless, we observed
that the addition of SFN inhibited the total HDAC activity and expression of HDAC6, which is
consistent with previous studies that have shown that SFN and its metabolites SFN-Cys and
SFN-NAC can inhibit HDACs (Myzak, Karplus et al. 2004; Myzak, Hardin et al. 2006).
Considering HDACs are commonly overexpressed in human and mouse colon tumors
(Mariadason 2008; Xu, Liu et al. 2016), SFN may be a promising adjunct dietary preventative
agent.

Without observing significant influences from the addition of SFN on inflammation and Wntsignaling, we examined another molecular mechanism, autophagy activity. Autophagy is an
evolutionarily conserved lysosomal degradation pathway that is essential for cellular
homeostasis and genomic integrity (Levine and Kroemer 2008). Its dysfunction has been linked
to a wide range of diseases including cancer. Previous studies have shown that VD and its
analogs can trigger autophagic death in many cancer cells (Wang, Lian et al. 2008; TaveraMendoza, Westerling et al. 2017). SFN can also initiate autophagy in several cell types (Jo, Kim
et al. 2014; Liu, Smith et al. 2017). Our data indicates that VD can activate colonic autophagy in
obese Apc638N mice, and VD and SFN co-supplementation further activate autophagy with a
statistically significant degree (p < 0.05). These findings suggest that the addition of SFN may
magnify the influences of VD on autophagy.
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5.6 Conclusions
In conclusion, we found that a high dose of VD supplementation decreased obesity-associated
intestinal tumorigenesis by decreasing the production of multiple proinflammatory cytokines, and
subsequently altering the tumorigenic Wnt pathway in the Apc1638N model. The addition of SFN
with a high dose of VD supplementation inhibited HDAC activity and further stimulated
autophagy. Our findings warrant further pre-clinical and clinical studies to explore the cancer
preventive effects of a high dose of VD and its combination with SFN supplementation on
obesity-associated CRC.
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CHAPTER 6
FFAR2 KNOCKDOWN MITIGATES ANTICANCER EFFECTS OF BUTYRATE BY
DYSREGULATION WNT/Β-CATENIN PATHWAY

6.1 Abstract
Previous studies have shown that butyrate is able to induce colon cancer cells apoptosis and
differentiation. However, the detailed molecular mechanism of butyrate in suppression of colon
cancer growth remains ambiguous. The present study aims to evaluate the mechanism by
which butyrate modulates colon cancer growth. Caco-2 cells were treated with 0 mM, 1 mM, 2
mM, 5 mM butyrate. MTT assay showed that 2 mM and 5 mM butyrate significantly induced cell
death by 17.9% and 41.2% respectively. In addition, western blot indicated that 2 mM and 5 mM
butyrate can significantly increase the expression of cleaved caspase 3 by 136% and 292%
respectively. We also found that butyrate can increase the activity of Wnt/β-catenin pathway.
Knocking down FFAR2 by siRNA decreased the expression of cleaved caspase 3 and the
expression of phospho-GSK3β (Ser9) and active β-catenin in Caco-2 cells, subsequently
mitigated the anticancer effect of butyrate. Based on these results, we conclude that FFAR2 is
required for the cytotoxicity effects of butyrate and regulation of Wnt pathway. Our findings
warrant further studies to explore the molecular mechanisms by which butyrate induces colon
cancer death.
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6.2 Introduction
Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is
the third most common cancer in the United States, with around 140,000 new cases being
diagnosed last year. The pathogenetic mechanisms underlying CRC development are complex
and include hereditary and environmental factors. There is strong evidence that dietary fiber
plays a protective role in CRC carcinogenesis (Gunter and Leitzmann 2006; Sengupta, Muir et
al. 2006).

The gut fermentation of dietary fiber by colonic bacteria produces short-chain fatty acids
(SCFAs). Butyrate, a four-carbon fatty acid, is a major energy source for colonocytes and
promotes colonocytes proliferation (Guilloteau, Martin et al. 2010). Butyrate causes reduction in
cancer cell proliferation by blocking the G1/S phase of the cell cycle (Vaziri, Stice et al. 1998).
Like trichostatin A (TSA), butyrate is a histone deacetylase inhibitor (HDACi), regulating proapoptotic protein expression by inhibiting HDACs. Cancer cells preferentially ferment glucose as
an energy source even when oxygen is abundant. Therefore, butyrate is accumulated in the
cancer cell cytoplasm, leading to an enhanced anticancer effects (Donohoe, Collins et al. 2012).

Free fatty acid receptor 2 (FFAR2) is a G-protein coupled receptor for SCFAs (acetate,
propionate, and butyrate). FFAR2 is preferentially expressed in normal colonocytes and
neutrophols. Previous studies have shown FFAR2 is crucial for the resolution of inflammation,
loss of FFAR2 might promote colon cancer by epigenetic dysregulation of inflammation
suppresspors, such as sfrp1, dkk3, socs1 (Pan, Oshima et al. 2018). However, the role of
FFAR2 in anticancer effects of butyrate is still not fully understood.
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6.3 Materials and Methods
6.3.1 Chemicals and reagents
The sodium butyrate and 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium Bromide
(MTT, Calbiochem®) was obtained from MilliporeSigma (Burlington, MA). Sodium butyrate was
dissolved in phosphate buffered saline (1X) (PBS, Gibco™) to make 1 M, 2 M, 5 M stock
solutions. MTT were dissolved in PBS to make a 5 mg/ml stock solution. Stock solutions were
prepared freshly before use in the fume-hood. The stock solution were then filter-sterilized.
Dulbecco's modified Eagle medium (1X) (DMEM, Gibco™), heat-inactivated fetal bovine serum
(FBS, Gibco™), 0.25% trypsin-EDTA (1X) (Gibco™), penicillin-streptomycin (10,000 U/mL)
(Gibco™), TRIzol® reagent (Invitrogen™), DEPC-treated water, high capacity cDNA reverse
transcription kit (Applied Biosystems™) and PowerUp™ SYBR™ green master mix (Applied
Biosystems™) were purchased from Thermo Fisher Scientific Co. (Waltham, MA). Goat antirabbit IgG-HRP and goat anti-mouse IgG-HRP antibodies were purchased from Santa Cruz
Biotechnology (Dallas, TX). phospho-GSK3β (Ser9), active β-catenin, cleaved-caspase 3
antibodies were purchased from Cell Signaling Technology (Danvers, MA).

6.3.2 Cell culture
Human colon cancer cell line Caco-2 was obtained from American Type Culture Collection
(ATCC). The Caco-2 cells were maintained in a 100 mm dish at 37°C in a 5% CO2 incubator in
Dulbecco's modified Eagle medium (1X) (DMEM, Gibco™), supplemented with a 10% heatinactivated fetal bovine serum (FBS, Gibco™), 100 U/mL penicillin and 100 μg/mL streptomycin
(Gibco™), and 1 mM sodium pyruvate. Cells were passaged at 80% confluency, and the
medium was changed every 72 hours.
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6.3.3 Cell-viability assay (MTT assay)
Cell viability was measured by the 3-(4,5-dimethylthylthiazol-2-yl)-2,5 diphenyltetrazolium
bromide (MTT) method, as reported previously (Li, Yue et al. 2014). Briefly, Caco-2 cells were
seeded in 96-well plates with 1×104 cells per well. After 70% confluency, suck the medium.
Cells were treated with DMEM containing 1% FBS and butyrate (1-5 mM with PBS) or control
medium containing 1% FBS for 48 hours. We added medium to the blank but did not seeding it.
Cells were then incubated with MTT (0.5mg/mL) for 1 hour. After dissolved in DMSO,
SpectraMax microplate reader (Molecular Devices, CA) were used to measure the absorbance
at 570 nm wavelength. The OD value read from treatment and control groups then subtract the
average OD value read from blank group. Results are expressed as the percentage of cell
viability compared to the control. Experiments were repeated at least three times to ensure
consistency of results.

6.3.4 Real-time PCR for gene expression
RNA samples were extracted from the colonic scrapings with Trizol reagent (Invitorgen,
Carlsbad, CA). The concentration as well as purity of RNA samples was measured using
NanoDrop 2000 (Thermo Scientific, Waltham, MA). The first-strand cDNAs were synthesized
from total RNAs using QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). Real-time
PCR was performed on the ViiATM 7 Real-Time PCR System (Applied Biosystems, Carlsbad,
CA) using the SYBR green PCR reagent kit (Invitrogen, Carlsbad, CA). The copy number of
each transcript was calculated with respect to the GAPDH copy number. Primer sequences and
thermal cycling conditions were listed as supporting information in APPENDIX B.

6.3.5 Western blot analyses
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As reported before (Sun, Yu et al. 2011), 40 μg of protein from each treatment was separated
by 10% SDS-PAGE and transferred onto a PVDF membrane. After blocking with 10% instant
nonfat dry milk, membranes were incubated with specific antibodies overnight at 4°C, followed
by incubation with the secondary antibody. Antibody binding was detected with the enhanced
ECL detection system. Notable western blots results were quantified using Image J software
after normalizing to a corresponding loading controls.

6.3.6 Small interfering RNA
Caco-2 cells were seeded in 6-well plates with 1×106 cells per well. Caco-2 were then
transfected by combining Lipofectamine RNAiMAX with Silencer Select small interfering RNA
(siRNA) targeting FFAR2 (Invitrogen, Carlsbad, CA) in Opti-MEM (Gibco™) for 48 hours. After
48 hours, siRNA complexes were removed and replaced with butyrate for another 48 hours.
Cells were extracted for following experiments.

6.3.7 Statistical analysis
Values in the text are presented as means ± S.E.M. One-way ANOVA (treatment) statistical
analyses were performed using Graphpad Prism 5 followed by multiple comparisons (Tukey
method) among all treatments (groups). To simplify data presentation in the figures, the
comparisons were only shown between the HF groups with other treatment groups. Values of p
< 0.05 were considered statistically significant among the comparisons. Fisher’s exact test was
used for tumor incidence. The expression of each gene was normalized to the housekeeping
gene GAPDH (DCt = Cttarget gene-CtGAPDH). Statistical analyses were performed based on ΔCt and
relative expression is reported as 2−ΔΔCt, where ΔΔCt=DCt-Experiment-DCt-Control.
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6.4 Results
6.4.1 Cytotoxicity of human colon cancer cell line Caco-2 in response to butyrate
We first examined the cytotoxicity effects of butyrate on Caco-2 cell line by using a cell viability
assay (MTT assay). MTT assay is a common colorimetric assay for assessing cell mitochondrial
metabolic enzyme activity that reduces MTT. Therefore, MTT assay basically uses
mitochondrial enzyme activity as an indicator of cell viability. The drugs that induce cytotoxicity
and mitochondrial dysfunction will reduce the enzyme activity leading to a lower OD reader.
Cytotoxicity of drugs can be indicated by the OD reader. Caco-2 cells were plated in a 96-well
plate and exposed to physiologically relevant concentrations of butyrate (1 mM, 2 mM, 5 mM).
After 48 hours treatment, 2 mM and 5 mM butyrate significantly induce cell death by 17.9% and
41.2%, while 1 mM butyrate has no significant cytotoxicity on Caco-2 cells (Figure 6.1).

Figure 6.1. Cytotoxicity of human colon cancer cell line Caco-2 in response to butyrate. A)
Caco-2 cells were treated with 0 mM, 1 mM, 2 mM, 5 mM butyrate for 48 h. Cell viability was
measured by the MTT assay. *p < 0.05, **p < 0.01. Data are mean ± SEM.
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6.4.2 Cell apoptosis of human colon cancer cell line Caco-2 in response to butyrate
Cysteine-aspartic proteases (Caspases) are a group of protease enzymes playing crucial roles
in apoptosis. Caspase 3 is one of the key caspases, as it can be activated by both extrinsic and
intrinsic pathway in apoptotic cells. Caspase 3 is initially synthesized as inactive proenzymes.
When caspase 3 is cleaved, it can be activated. We therefore measured the protein levels of
cleaved caspase 3. We found that 2 mM and 5 mM butyrate can significantly increase the
expression of cleaved caspase 3 by 136% and 292% respectively, which indicating butyrate can
induce Caco-2 cell apoptosis (Figure 6.2).

Figure 6.2. Cell apoptosis of human colon cancer cell line Caco-2 in response to butyrate. A)
Representative Western blots and relative quantification of cleaved caspase 3. Data are
presented as the mean ± SEM. *p < 0.05, **p < 0.01.

6.4.3 Wnt/b-catenin pathway activity of human colon cancer cell line Caco-2 in response
to butyrate
We further studied the effects of butyrate on signaling pathways involved in CRC. It is well
known that aberrant Wnt signaling plays a crucial role in colorectal oncogenesis and
85

progression. By immunoblotting analysis, we measured the levels of phospho-GSK3β (Ser9)
protein, the inactive form of GSK3β, and the dephosphorylated β-catenin (Ser37 or Thr41)
protein, the active form, which are two key molecules in the Wnt pathway. As shown in Figure
6.3B, butyrate increases the expression of phospho-GSK3β (Ser9) and active β-catenin in a
dose dependent manner in Caco-2 cells. We further examined the mRNA expression of Wnt
pathway downstream oncogenes, c-Jun, c-Myc, and cyclin D1. We found that the mRNA
expressions of these downstream genes were increased in response to butyrate (Figure 6.3B).
This observations were consistent with the previous reports (Bordonaro, Lazarova et al. 2008;
Bordonaro, Lazarova et al. 2008).

Figure 6.3. Wnt/b-catenin pathway activity of human colon cancer cell line Caco-2 in response
to butyrate. A) Representative Western blots and relative quantification of GSK-3β Ser9
phosphorylation and active β-catenin in response to butyrate. B) mRNA expression of Wnt
pathway downstream genes in response to butyrate. Data are presented as the mean ± SEM.
*p < 0.05, **p < 0.01.
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6.4.4 FFAR2 knockdown mitigates anticancer effects of butyrate by dysregulation Wnt/βcatenin pathway
We first measured the mRNA expression of FFAR2 (butyrate receptor) and MCT1 (butyrate
transporter). As shown in Figure 6.4A, we found that butyrate dose dependently increased the
mRNA expression of FFAR2 and MCT1. We then tested whether butyrate induced Caco-2 cell
death and activation of Wnt/β-catenin pathway were through the FFAR2. As shown in Figure
6.4B, knocking down FFAR2 by siRNA decreased the expression of cleaved caspase 3 and the
expression of phospho-GSK3β (Ser9) and active β-catenin in Caco-2 cells. We further
examined the mRNA expression of Wnt pathway downstream oncogenes, c-Jun, c-Myc, and
cyclin D1. We found that the mRNA expressions of these downstream genes were decreased in
FFAR2 knock down Caco-2 cells (Figure 6.4C). As shown in Figure 6.4D, knocking down
FFAR2 by siRNA mitigated the anticancer effects of butyrate. Based on these results, we
conclude that FFAR2 is required for the cytotoxicity effects of butyrate and regulation of Wnt
pathway.
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Figure 6.4. Effect of FFAR2 knock down on the Caco-2 cell apoptosis and the activation of
Wnt/β-catenin pathway. A) mRNA expression of FFAR2 and MCT1. B) Western blotting. C).
mRNA expression of c-Jun, c-Myc, cyclin D1. D). Cell viability. Data are presented as the mean
± SEM. *p < 0.05.

6.5 Discussion
Colorectal cancer (CRC) is the third leading cause of cancer death in the United States in both
men and women. In 2018, it is estimated that ≈ 64 640 women and 75 610 men in the United
States were diagnosed with CRC and 23 240 women and 27 390 men died from CRC.
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Therefore, it is necessary and urgent to design efficient and economic strategies to prevent
CRC.

Substantial epidemiologic and experimental studies have shown that higher intake of dietary
fiber is associated with a lower risk of CRC (Levi, Pasche et al. 2001; Aune, Chan et al. 2011;
Kunzmann, Coleman et al. 2015). Colonic bacterial fermentation of dietary fiber can produce
butyrate, a short chain fatty acid. One of the explanations of CRC prevention effect of butyrate is
that bacterial fermentation converts resistant starch to SCFA (Song, Garrett et al. 2015). Among
SCFA, butyrate plays a pivotal role in the prevention/inhibition of colon carcinogenesis (Manning
and Gibson 2004). Butyrate can induce colon cancer cell differentiation and apoptosis, and
inhibit colon cancer cell differentiation (Goncalves, Araujo et al. 2011). Similarly, several animal
studies also suggested a protective effect of butyrate on CRC carcinogenesis (D'Argenio,
Cosenza et al. 1996; Kameue, Tsukahara et al. 2004; Lu, Nakanishi et al. 2013). Human studies
also found an inverse relationship between the levels of butyrate in the human colon and the
incidence of CRC (Bingham, Day et al. 2003). The risk of developing tumors are higher in the
distal colon where the concentration of butyrate is lower, implicating butyrate has CRC
prevention effect (Mortensen, Holtug et al. 1988). In consistent with these studies, we found that
butyrate (5 mM) significantly induce Caco-2 cell death by 41.2% and increased expression of
cleaved caspase 3.

Butyrate can support growth of normal colonocytes, interestingly it exerts a drastic inhibitory
effect on CRC (Bergman 1990). The possible explanation of this controversy might lie in the
Warburg effect which is observed in various cancer cells (Bates 2012). Normal colonocytes use
aerobic respiration to meet energy requirements, while colon cancer cells prefer anaerobic
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glycolysis even when there is plenty of oxygen. In colon cancer cells, because of excessive
anaerobic glycolysis, fatty acid oxidation is inhibited. Therefore, butyrate, a short chain fatty
acid, is not used as an energy resource and subsequently accumulate in the colon cancer cells.
The elevated level of butyrate can act as an HDACi and induce cancer cell apoptosis
(Encarnacao, Abrantes et al. 2015; Bultman 2016).

Besides butyrate can act as an HDACi, butyrate might exert anti-proliferative and pro-apoptotic
effects through manipulating several signal pathways in cancer cells. For example, sodium
butyrate (2.5 mM and 5 mM) increases the mRNA and protein expression of SMAD3 and
potentiates TGF-b signaling and its tumor suppressor activity in rat intestinal epithelial (RIE-1)
cells (Nguyen, Cao et al. 2006). Butyrate (5 mM) pretreatment followed by TGF-b treatment
increased DNA fragmentation and apoptosis in RIE-1 cells. Interestingly, without butyrate
pretreatment, TGF-b treatment alone cannot induce apoptosis and DNA fragmentation (Cao,
Gao et al. 2011). Butyrate (5 mM) can also arrest the RIE-1 cells in the G2/M phase of the cell
cycle.

Wnt signaling is crucial for intestinal crypts homeostasis and maintenance of intestinal stem
cells (Flanagan, Austin et al. 2018). It is well known that hyperactivation of Wnt pathway is
present in almost all CRC. Wnt signaling plays a pivotal role in CRC incidence and is the basis
for CRC tumorigenesis in patients with familial adenomatous polyposis and in Apc mutant mice
model. Loss of APC function is the main driver of CRC carcinogenesis. However, we found that
butyrate increased the expression of phospho-GSK3β (Ser9) and active β-catenin in a dose
dependent manner in Caco-2 cells. It is suggested that an optimal but not excessive activation
of Wnt/β-catenin pathway are favorable for cancer cell growth (Leedham, Rodenas-Cuadrado et
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al. 2013). Therefore, butyrate (5 mM) might activate Wnt/β-catenin pathway which surpass the
optimal level in Caco-2 cells.

Free fatty acid receptor 2 (FFAR2) is a G-protein coupled receptor for SCFAs (acetate,
propionate, and butyrate). Previous studies have shown that loss of FFAR2 might promote
colon cancer by epigenetic dysregulation of inflammation suppressors (Pan, Oshima et al.
2018). Our finding from this study demonstrated that knocking down FFAR2 by siRNA
decreased the expression of cleaved caspase 3 and the activity of Wnt/β-catenin pathway. In
addition, knocking down FFAR2 by siRNA mitigated the anticancer effects of butyrate. ‘

6.6 Conclusions
Based on these results, we conclude that FFAR2 is required for the cytotoxicity effects of
butyrate and regulation of Wnt pathway. Our findings warrant further studies to explore the
molecular mechanisms by which butyrate induces colon cancer death.
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CHAPTER 7
SUMMARY AND CONCLUSIONS
CRC has a high incidence rate, and an unhealthy diet and life style is an important risk factor.
The prevalence of obesity was 39.8% among US adults population and obesity can also
increase the risk of CRC. Therefore, many research have conducted to study the role of obesity
in the CRC risk and the mechanisms by which obesity increase the incidence of CRC. However,
the detailed molecular mechanisms need to be further addressed.

In our study, we utilized genetic approach and dietary strategies to study the prevention of diet
induced obesity associated CRC and determine the underlying molecular pathways that render
the CRC prevention effects.

We found that loss of TNF-α decreased obesity associated intestinal tumorigenesis by
decreasing the inflammation, and manipulating the β-catenin pathway and NF-kB signaling. In
addition, IKK, component of the NF-kB signaling, was involved in the regulation of β-catenin
pathway. The administration of Vitamin D (VD), at 5000 IU level, exerted an anti-inflammatory
property, and leaded to suppressed intestinal Wnt-signaling and tumorigenesis in obese mice.
The molecular function of sulforaphane on a high dose of VD supplementation, although
displayed on the inhibition of HDAC and the activation of autophagy, needs further investigation.
Butyrate can increase the activity of Wnt/β-catenin pathway. Knocking down FFAR2 by siRNA
decreased the expression of cleaved caspase 3 and the expression of phospho-GSK3β (Ser9)
and active β-catenin in Caco-2 cells, subsequently mitigated the anticancer effect of butyrate.
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In conclusion, we found that genetic approach and dietary strategies might be an effective
method to prevent CRC incidence and development.
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APPENDIX A

TABLE OF COMPOSITIONS OF THE EXPERIMENTS DIETS
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APPENDIX B
TABLE OF PRIMERS USED FOR REAL-TIME PCR ANALYSIS

Gene
Cyclin D1
c-Myc
c-Jun
Axin2

Forward Primer
5'-GCGTACCCTGACACCAATCTC-3'
5'-ATGCCCCTCAACGTGAACTTC-3'
5'-TTCCTCCAGTCCGAGAGCG-3'
5'- ATGAGTAGCGCCGTGTTAGTG-3'

Reverse Primer
5'-ACTTGAAGTAAGATACGGAGGGC-3'
5'-GTCGCAGATGAAATAGGGCTG-3'
5'-TGAGAAGGTCCGAGTTCTTGG-3'
5'- GGGCATAGGTTTGGTGGACT-3'

*Thermal Cycling Conditions: UDG activation 50°C 2mins, Dual-Lock DNA polymerase 95°C 2mins. Denature
95°C 1s, Anneal/extend 60°C 30s, 40 Cycles.
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